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ABSTRACT

Learn biological meaningful representations with transfer learning
by
Di He

Advisor: Lei Xie, Ph.D
Machine learning has made significant contributions to bioinformatics and computational biol
ogy. In particular, supervised learning approaches have been widely used in solving problems such
as biomarker identification, drug response prediction, and so on. However, because of the limited
availability of comprehensively labeled and clean data, constructing predictive models in super
vised settings is not always desirable or possible, especially when using datahunger, redhot learning
paradigms such as deep learning methods. Hence, there are urgent needs to develop new approaches
that could leverage more readily available unlabeled data in driving successful machine learning ap
plications in this area.
In my dissertation, I focused on exploring and designing deep learningbased unsupervised
representation learning methods. A consistent scheme of these methods is that they construct a low
dimensional space from the unlabeled raw datasets, and then leverage the learned lowdimensional
embedding explicitly or implicitly for diverse downstream supervised tasks. Although progresses
have been made in recent years, most deep learning applications in biomedical studies are still in
their infancy. It remains a challenging task to fully extract the biological meaningful information
from a biomedical dataset such as multiomics data to support predictive modeling for practical tasks
of interest. To improve the biological relevance of learned representations, innovative approaches
that could better integrate mulitomics data and utilize their specific characteristics and natural ”anno
tations” are needed.
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Hence, we proposed two approaches, namely, Cross LEvel Information Transmission (CLEIT)
network and Coherent Cellline Tissue Deconfounding Autoencoder (CODEAE). Specifically,
CLEIT aims to leverage the hierarchical relationships among omics data at different levels to drive
the biologically meaningful representation learning, and CODEAE learns biologically meaningful
representations by explicitly deconfounding the confounding factors such as data source origins.
As the benchmark results showed, these two methods are able to improve knowledge transfer be
tween multiomics data, and invitro and invivo samples respectively, and significantly boost re
spective performance in drug response prediction task. Thus, they are potentially powerful tools for
precision medicine and drug discovery.
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Chapter 1
Introduction

With the emergence of sequencing techniques and later high throughput techniques such as mi
croarray and nextgeneration sequencing (NGS) [1], biomedical studies are partially liberated from
the limited availability of data. As a result, the demand for modern computational methods to inter
pret the increasingly massive data is triggered. It is evident that biology is set to become a highly
quantitative science instead of a basic qualitative descriptive one. Therefore, computational biol
ogy came into being. According to the National Institute of Health (NIH), computational biology
includes the development and application of dataanalytical and theoretical methods, mathematical
modeling and computational simulation approaches to the study of biological, behavioral, and social
systems [2].
Due to the inherent complexity within biological systems, it is obvious that hand hardcoded
methods can seldom get the analysis done effectively. That’s when learning based approaches came
into play. Machine learning has the capability of discovering hidden patterns and constructing pre
dictive models without making strict assumptions in advance. Thus, it has become one of the major
players in computational biology. Despite a wide spread of successful computational biology appli
cations, the performance of most machine learning methods is empirically shown to be highly depen
dent on the data representations or features used. In practice, much of the efforts in deploying ma
chine learning methods go to the feature designs. Initially, features are usually knowledgebased and
engineered by domain experts through years of trial and error. Such a process is generally considered
as feature engineering, In the early days, when the scale and diversity of biomedical data were still
relatively limited, to take advantage of humanprior knowledge is a great way to improve the inter
pretability and generality of learned biological models as well as to guarantee the initial successful
applications of machine learning in biomedical studies. However, when faced with more diverse data
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as we have nowadays, feature engineering approaches are not sufficient to support satisfactory work.
Firstly, the complexity of the data will make the existing domain knowledge inadequate. Secondly,
the scale of the data could merely make the labor required in manual feature engineering unaccept
able.
Therefore, to expand the scope and ease the applicability of machine learning, it would be
highly desirable to make learning algorithms less dependent on feature engineering and come up
with an automated process that can learn ”good” features itself  representation learning or feature
learning rooted from such growing realization. Generally speaking, representation learning is a set of
techniques that learn data transformation that converts raw data input into a new feature space where
the information can be somehow more easily and effectively exploited in machine learning tasks.
Representation learning obviates manual feature engineering and allows a machine to both learn at
a specific task (using features) and learn the features themselves (to learn how to learn). Although
”What is a good representation” or a common objective for representation learning is not yet estab
lished, learned representations are generally expected to be capable of identifying and disentangling
the underlying explanatory factors hidden in the observed lowlevel sensory data and facilitate the
following supervised or reinforcement learning tasks [3]. In addition to the focus of downstream ma
chine learning task performance in the design of feature learning methods, a common strategy used
in representation learning is to explicitly inject some clues or prior assumptions over the learned rep
resentations to help guide the learning process. Here we summarized some examples of priors that
could be generally helpful for representation learning.
• Manifolds (or lower dimensionality): realworld data presented in highdimensional data
spaces are likely to concentrate on the vicinity of a manifold M of much lower dimensional
ity, embedded in a highdimensional space where the data lives. Also, a lowerdimensional
representation is preferred since it can be helpful to alleviate the high dimensionality curse.
• Disentanglement of explanatory factors: observations are assumed to be generated by multi
ple underlying explanatory factors of variation and the dependencies on such factors should
be simple, typically linear dependencies. More preferably, the factors are statistically uncorre
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lated or independent from each other.
• Distributed representation: the representation learned is expected to be expressive, meaning
that a reasonablysized learned representation should be able to capture a large number of in
put configurations (concepts). Distributed representation is the most typical way to achieve
such expressiveness, which offers exponential gains over more local approaches such as one
hot representation. Specifically, within a distributed representation, k out of N representation
elements or features values can be independently varied, and the combinatorial value of such

k features are used to represent concepts. In addition, each representation element can be in
volved in representing multiple concepts.
• Sparse representation: A special case of distributed representation, where k is required to be
strictly smaller than N , which means that for any given input configuration, only a small frac
tion of the possible is relevant. In terms of representations, this could be demonstrated by fea
tures that are often zero, or by the fact that most of the extracted features are insensitive to
small variations of input.
• Hierarchical organization of explanatory factors: the concepts that are useful for describing
the world often can be defined by other concepts in the hierarchy, with more abstract concepts
higher in the hierarchy, defined in terms of less abstract concepts.
Just like almost all other kinds of data, data with comprehensive or accurate annotations (la
bels) in biomedical studies are still relatively limited and often expensive to obtain, and in such sce
narios, generalizable supervised learning is not always possible. Hence, to achieve successful ma
chine learning applications in this area requires us to devise proper approaches to leverage the more
abundant unlabeled data. Such needs increased the necessity of unsupervised representation learning
methods, which gained its revamped popularity along with deep learning, which offers a promising
solution to make good use of unlabeled data in an unsupervised, semisupervised or more recently
selfsupervised manner. In particular, unsupervised representation learning is aiming to uncover the
hidden structure of the data at hand, and then use the learned transformation (encoding process) to
help boost other tasks’ performance. In particular, a consistent scheme of these methods is that they
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Figure 1.1: Example of Hiearchical Multiple Levels of Omics Data. Figure appeared in [9].

construct a lowdimensional space from the unlabeled raw datasets, and then leverage the learned
lowdimensional embedding explicitly or implicitly for diverse downstream supervised tasks. This
popular approach ,pretraining finetuning approach, originated from the work [4] where a detailed
discussion on the benefits of pretraining is given and has gradually gained more and more attention
with the effective applications in both computer vision studies such as [5, 6] and natural language
processing tasks such as [7, 8]. Though sharing some commonalities, the complex and heteroge
neous nature of biomedical data requires us to actively adapt and devise innovative representation
learning methods that tailor to the organization and specifics of biomedical data in addition to the
aforementioned feature learning generic priors and successful applications in other areas. And ul
timately we could present biologically meaningful representation learning frameworks that would
benefit miscellaneous downstream tasks of biological and clinical interests.
In particular, to comprehensively understand human health and diseases requires interpretation
of molecular intricacy and variations at multiple levels of the hierarchical biological system, such as
genome, epigenome, transcriptome, proteome and metabolome [10] as shown in Figure 1.1. With
the advancement of highthroughput sequencing techniques, we have been able to generate and col
lect data at these levels, which together is called as ”multiomics” data. Informally, the word ‘omics’
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Figure 1.2: Example of MultiOmics Data Repositories. Figure appeared in [10].

refers to a field of study in biology ending in omics, such as genomics, transcriptomics, proteomics
or metabolomics, which reflects their corresponding study objects, such as the genome, transcrip
tome, proteome, and metabolome of organisms, respectively. Omics aims at collectively character
ing and quantifying miscellaneous biological molecules that translate into structure, function, and
dynamics of organisms. Different omics data capture different perspectives of a biological system.
Some of the notable data repositories for multiomics data are listed in Figure 1.2.
Such abundance and diversity of omics data have enlarged the possibility of finding solutions
to more biological problems. Take transcriptomics data as an example, transcriptomics is a powerful
technique to characterize cellular activity under various conditions, allowing researchers to uncover
the underlying associations among genes, biological pathways, diseases, and environmental factors.
Hence, this data source has been widely explored by studies ranging from regulatory gene identifica
tion [11, 12] to disease biomarker discovery [13]. Further, the emergence of pharmacogenomics data
[14], which records cell lines’ multiomics profiles and their drug responses against a range of drug
agents provide exciting rich data resources for development of personalized medicine, such as in [15,
16]. Despite the rich data sources and promising prospective brought by multiomics data, there are
several major challenges in delivering successful multiomics data integration and followingly con
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struct practical useful predictive models. Firstly, the complex nature of the biological system and
lack of ”fundamental biological principles” result in the absences of generic guidelines of formaliz
ing biological problems. Secondly, the inherent heterogeneity of multiomics data due to the increas
ing diversity of experimental techniques make integration of multiomics data very difficult if not
impossible. Thirdly, due to biological variability and precision limits, raw multiomics data is often
full of noise. Last but not least, multiomics data analysis is a sufferer of high dimension curse, due
to the data’s highdimensionality and relatively small sample quantity, especially samples with co
herent annotations. On the one hand, the highdimensionality of data will make the interpretation of
the learned results extremely difficult; on the other hand, it will also make it problematic to achieve a
statistically significant result. Hence, it would be beneficial to explicitly explore available representa
tion learning methods and develop new methods to accommodate the everincreasing needs to better
understand the multiomics data in practice and thus push the frontier of applying machine learning
methods in biomedical studies.
In my works, I explored the potential usefulness of aforementioned classical pretraining fine
tuning schemes in leveraging unlabeled data to boost performance of downstream supervised tasks
such as drug sensitivity prediction. In addition, by utilizing the information hidden in the ”natural”
annotations associated with the multiomics data, we have shown that such information could help
to further improve the feature learning effectiveness and meaningfulness in Cross LEvel Information
Transmission (CLEIT) network and Coherent Cell lineTissue Deconfounding Autoencoder (CODE
AE).
In particular, CLEIT aims to leverage the hierarchical relationships among omics data at differ
ent levels to drive the biologically meaningful representation learning. In addition, due to the infor
mation transmission from DNA to phenotype involves multiple intermediate levels of RNA, protein,
metabolite, etc. The higherlevel features (e.g., gene expression) usually have stronger discriminative
and interpretable power than the lower level features (e.g., somatic mutation). However, in clinical
practice, patients’ mutation profiles are more often directly involved in the selection of therapies.
CLEIT could build effective model that can perform anticancer drug response prediction with only
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mutation data.
CODEAE, on the other hand, aims to learn biologically meaningful representations by explic
itly deconfounding the confounding factors such as data source origins. Moreover, due to the lack
of large number of patient samples with drug treatment and response history, most drug response pre
dictive studies to date have mainly utilized omics profiles from panels of invitro cancer cell lines as
input features. However, the model build with invitro cell line samples’ applicability in predicting
clinical patients’ response against chosen therapeutic agents is not guaranteed, because of the genetic
and environmental differences between invitro cell lines and patientderived tissue samples and con
founding factors that may mask intrinsic biological signals. CODEAE can better extract common
biological signals shared by incoherent invitro and invivo samples and thus transfer knowledge
learned from cell line data to tissue data while separate confounding factors.
Both CLEIT and CODEAE explicitly use the ”domain differences” information to guide the
representation learning, thus a wide range of domain adaptation techniques, particularly feature
based domain adaptation methods are refereed and compared [17].
In summary, I will present an overview of the representation learning methods and feature
based domain adaptation approaches in Chapter 2, followed by a comparative study on a variety of
autoencoders in drug response prediction task in Chapter 3. In Chapter 4 and Chapter 5, I will detail
the framework of Cross LEvel Information Transmission (CLEIT) network and Coherent Cell line
Tissue Deconfounding Autoencoder (CODEAE) and report their respective benchmark performance
against other stateofart methods. In Chapter 6, I will conclude my dissertation with a summary of
my works and discuss the prospectives of related research directions..
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Chapter 2
Method Review

Overview of Representation Learning

Generally speaking, representation learning aims at seeking a transformation of the raw data
that somehow makes it easier to extract information from it when building classifiers or other predic
tors. The fundamental idea of improving supervised tasks with unsupervised learned features is that
the features useful for unsupervised tasks should be also helpful for the supervised tasks. Throughout
the years, there have been many successful examples. There are two main formalisms of representa
tion learning methods, namely representation learning as direct mapping, and representation learning
as a probabilistic model.
Representation learning as direct mapping Representation learning can be seen as seeking a

direct mapping procedure that transforms raw input into a new feature space possessing some desired
properties to facilitate followon tasks. Mathematically, in its simplest sense, such transformation
could be explicitly parametrized as a function f in the following,

f :x→z

(2.1)

where x ∈ Rd stands for raw samples in the original ddimension space, and z ∈ Rq is the learned
representation of original raw sample. In this case, we can also think f as an encoding function that
encodes the raw data to certain hidden codes. Depending on the formations of f , such mapping pro
cedures can be categorized into shallow models if no nested functions are involved, or deep model
otherwise. Furthermore, to learn f , an objective function needs to be employed in advance. In the
setting of unsupervised learning, because of the absence of the target labels, objective functions in
use are often a metric that can measure a “distance”like cost between raw input and new represen
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tation such as mean squared error in the form of either L(x, z) or L(x, g(z)) ,where g is a decoding
function, or L(z), a direct measurement of the quality of the learned representation. Additional reg
ularization terms are also commonly included in the objective functions to explicitly or implicitly
demonstrate the prior knowledge or preference over the model.
Representation learning as probabilistic modeling Different from direct mapping, where

the observations are directly encoded into another representation, representation learning can be for
malized as a probabilistic model, where typically a list of latent variables are involved. The latent
variables are assumed to be underlying explanatory factors of variation that generated the data. From
the probabilistic modeling perspective, the question of representation learning can be interpreted as
an attempt to recover a parsimonious set of latent random variables that describe the most probable
distribution over the observed data [18]. Under this framework, it is fundamentally assumed that the
responses on the observed variables are the results of different configurations over the latent vari
ables.
Formally, we can express such framework as an attempt to model the joint distribution of ob
served variables and latent variables, i.e.,P (x, z), where x is a vector of observed variables in space

X (∈ Rd ) and z is the vector of latent variables in the space Z from which we can easily sample
from some prior probability density function (PDF) P (z) over Z ∈ Rq . Typically, the model can be
learned by estimating a set of model parameters that maximize the likelihood of the training data, the
likelihood of one particular training sample can be calculated as,
Z

P (x) =

P (x|z)P (z)dz

(2.2)

Similar to direct mapping, additional regularization constraints can also be added to further guide the
training. The feature learning process can then be conceived as the inference process to determine
the posterior probability distribution of the latent variables given the observations (or realizations of
observed variables), i.e., P (z|x). Last but not least, a posterior distribution over latent variable is not
yet a simple, usable feature vector that can be fed into following tasks, and actual values for the new
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features need to be further derived from that distribution, for example, taking the latent variable’s
expectation.
In summary, representation learning is all about to learn a new representation of the raw input
so that the desired properties possessed by the new representation can facilitate followon tasks. The
apparent advantage of formalizing representation learning as mapping is simple and straightforward,
yet how to interpret the learned representation properly is very challenging. On the other hand, from
the probabilistic modeling perspective, we could have a straightforward interpretation of the new
representation learned since the latent variables could be naturally associated with the explanatory
factors. Yet the legibility and usefulness of learned latent variables as well as the optimization in
volved could be very challenging. Thus, I will interpret the following representative feature learning
methods from two perspectives if appropriate. Further, the idea of representation learning or feature
learning has existed for decades, yet the popularity gained in recent years is primarily due to the re
naissance of deep learning methods. To distinguish the deep learningbased saints from others, I will
thus split the methods reviewed here into two main categories, shallow and deep model.

Shallow model based representation learning methods

Classical shallow model based representation learning methods include Principle Component
Analysis, Independent Component Analysis and sparse coding, as well as their notable extensions.
PCA

Principal component analysis (PCA) [19, 20] is a statistical procedure that seeks linear combi
nations of the original variables such that the derived variables could capture the maximal variance
within the data in an orderly fashion. Specifically, PCA uses an orthogonal linear transformation to
project a set of observations of possibly correlated variables into a new space of linearly uncorrelated
variables (called principal components). The transformation is defined in such a way that the first
principal component in the derived space has the largest variance, and each following component,
in turn, has the highest possible variance under the constraint that it is orthogonal to the preceding
components. By definition, the first few principal components possess most of the variance (or statis
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tical information), thus only first few components will be selected to represent the original data while
preserving as much as “variability” as possible. PCA is primarily used as a dimension reduction and
data exploratory technique. Mathematically, PCA can be formalized as,
b = XW
X

(2.3)

subject to WT W = I and I is the identity matrix.
where X ∈ Rd stands for the raw input. Loading matrix W ∈ Rd , is an orthogonal matrix
b . Each
responsible for transforming the raw input matrix X into a new ddimensional representation X
b is called principal component, which essentially is a
column (feature) of the transformed matrix X

linear combination of the original features. As mentioned above, PCA will only keep the first q prin
cipal components as the new representation of the raw data, correspondingly only the truncated load
ing matrix Wq which only includes the first q loading vectors needs to be constructed. Mathemati
cally, we can present Wq as,
b q = XWq
X

(2.4)

subject to WTq Wq = I and I is the identity matrix.
b q is the new representation, and it can be mathematically proved that X
b q ∈ Rq pre
where X

served the maximum variance of original data for any given q , while minimized the reconstruction
error defined as following,
b T −X
b q WT
XW
q

2
2

(2.5)

In practice, PCA can be done through either the singular value decomposition of data matrix X (after
columnwise centering) or eigenvalue decomposition of data covariance matrix XT X. PCA is con
sidered as the optimal orthogonal transformation for obtaining a subspace while preserving most of
the variance in original data. Besides, there is no underlying data distribution assumption required in
PCA, hence making PCA highly adaptable.
Although PCA is probably the oldest and most widely used feature extraction technique and
has been seen as one of the goto methods when it comes to build benchmark representation learning
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framework, inherently it has certain shortcomings. Firstly, because typically a columnwise center
ing is required for PCA processing, PCA is highly sensitive to the noise in the data. Robust PCA
[21] decomposes the raw data matrix into two components of same size as original input: a lowrank
component that corresponds to general data pattern and a sparse component corresponds to distur
bances to alleviate PCA’s sensitivity towards noises. Secondly, transformed features obtained from
PCA are considered as a linear combination of all original variables, if the original variables are in a
highdimensional space, how to leverage the contributions from raw features is problematic, which
in the end makes the interpretation of learned features very challenging. Sparsity constraints on load
ing matrix [22, 23] are introduced to make the learned features combinations from a relative small
number of orginal features and thus improved the interpretation power. Moreover, similar to the ker
nel trick from [24], Kernel PCA [25] were proposed to obtain nonlinear principal components and
combat the limited modeling capacity and inability to understand the complex interactions between
any input variables of the original linear PCA. Last but not least, in [26], the authors formalized PCA
as a Gaussian latent variable model and computed principal components via likelihood maximization,
which provided an alternative probabilistic perspective of PCA and improved PCA’s interpretability.
ICA

Independent Component Analysis (ICA), another rich family of feature extraction technique,
is among the oldest representation learning algorithms. ICA learns a linear transformation that could
separate the observed variables into many understandable signals (sources), and these signals are
intended to be fully independent (rather than merely decorrelated from each other) [27]. In the end,
the recovered (learned) sources can be used as the new representation of the raw data. The major
contribution of ICA was the realization that the model can be made identifiable by making the uncon
ventional assumption of the nonGaussianity of the independent latent variables (components).
ICA originated as a classical solution to the blind source separation task (BSS) [28] . Consider
random observational variables denoted by xi (t) , i = 1, 2, . . . , d, t = 1, 2, . . . , n, here t is the
index of the observations (or time index in BSS) and d is the index of the observed variables. In ICA
assumes observations can be derived as linear combinations of statistically mutually independent
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latent (hidden) variables zj (t) , j = 1, 2, . . . , q , via some unknown mixing coefficients aij . Without
taking noise into consideration, ICA model can be formalized as,

xi (t) =

q
X

aij zj (t)

(2.6)

j=1

for all i = 1, 2, . . . , d.
Further if we drop the sample index t, and denote observation variables and latent variables as
vector x ∈ Rd and z ∈ Rq , and then formulate mixing coefficients as a mixing matrix of shape d × q .
Then, ICA model becomes,
x = Az

(2.7)

To recover the latent variables z from corresponding observed vector x, we need to first estimate an
unmixing matrix such that,
b
z

= Wx

(2.8)

For simplicity, ICA model assumes mixing matrix A to be square and invertible so that unmixing
matrix W = A−1 . To estimate the unmixing (mixing) matrix, a specific objective needs to be set up.
As the major breakthrough of ICA, intuitively it was proved [27] that the maximization of the non
Gaussianity of components can lead to the independent components as desired in ICA model. So,
ICA estimation could be done by adaptively calculating an unmixing matrix that transforms obser
vations to independent latent components with the maximization of nonGaussianity of components
as objective. Common quantitative nonGaussianity measure includes Kurtosis and Neoentropy. Al
ternatively, ICA estimation could also be done via the minimization of mutual information among
independent components, or by maximum likelihood estimation when treat ICA as a linear genera
tive model with nongaussian independent latent variables. Popular ICA algorithms include FastICA
[29] and Infomax [30].
One of the assumptions in basic ICA is that the number of observed variables should be equal
to the number of sources (latent variables). Obviously, in reality this condition can be not satisfied
always. So, ICA is further split into undercomplete and overcomplete ICAs. Undercomplete ICA,
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stands for the condition that the number of sources is smaller than the number of observed variables.
It can be solved by first applying dimension reduction methods (such as PCA) to transform the ob
served data to have the same dimensionality as the sources, then standard ICA algorithm can be
adopted to obtain the estimates of the independent sources. On the other hand, overcomplete ICA,
stands for the condition that the number of sources is bigger than the number of observed variables.
Typically, it can be solved by ideas stemming from sparse coding [31]. Notable methods include [32,
33].
Sparse Coding

Similar to ICA, sparse coding also relates a list of latent variables z to the observed variables x
through a linear mapping (W, called dictionary in sparse coding). In addition, sparse coding includes
a penalty to ensure only a sparse activation of z (i.e. one with many features set to exactly zero) is
used to encoder each input x. From a direct mapping perspective, sparse coding can be seen as con
structing a sparse code associated with the input x via:
z∗ = f (x) = argminz ∥x − Wz∥2 + λ ∥z∥
2

(2.9)

The dictionary W can be learnt by minimizing the following training objective with respect to W:
X
i

x(i) − Wz∗(i)

2
2

(2.10)

where x(i) is the ith example and z∗(i) is the corresponding sparse code calculated the above formula.
Further, to guarantee the identifiability of (W, (W is usually constrained to have unitform columns.
Alternatively, sparse coding can also be viewed from a probabilistic perspective. Sparse coding uses
a sparsityinducing Laplacian prior over the sparse codes and can be solved by expectation maxi
mization algorithm [34].
Spikeandslap sparse coding (S3C) [35] is one of the variants of sparse coding specialized
in unsupervised feature learning. The S3C model splits the latent variables into two individual set,
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namely, a set of latent binary spike variables , and a set of realvalued slab variables. S3C model
used the set of binary spike variables to explicitly control of the sparsity pattern of latent variables,
while sparse coding place a factorial prior on latent variables such as Laplace distribution to encour
age the posterior mode to be sparse. Similar to sparse coding, the learning and inference of S3C
model can be done with variational EM algorithm.
Aforementioned PCA, ICA, sparse coding methods have been adopted in highdimensional
multiomics data analysis primarily as dimension reduction techniques to support effective statisti
cal machine learning, such as PCA in [36, 37, 38]. In [39], PCA was applied over the gene expres
sion data in an attempt to capture the underlying cluster structure. However, due to the statistical
procedural nature of PCA, there are no effective ways to incorporate biological consideration into
the learned representation. For the reallife dataset, it is often the case that the observed data con
tain many signals mixed up, so ICA is a natural fit to complete the unmixing. For example, a gene
expression level may originate from many biological processes or underlying biological factors. In
most scientific studies, the original signals or processes (or underlying explanatory factors) are ex
actly the targets we want to recover. ICA then can be used to decompose input data into components
so that each component is statistically as independent from each other as possible and potentially re
veal the underlying patterns as a result. Notable applications include [40, 41], in which ICA is used
to make effective and accurate detection of gene clustering patterns via statistical analysis of omics
data, and [42, 43] where ICA is used for identification of cancer and oncogenic pathways. However,
the number of ICs to be decided in advance is also a challenging task. Moreover, the biological sig
nificance of ICs extracted is not guaranteed. Sparse coding is another widely used tool dealing with
highdimensional data. By incorporating sparse coding and local linear mapping, the authors of [44]
achieved high accuracy in a classification task. In [45], various sparse coding and dictionary learning
models are discussed and compared towards a classification task. Sparse linear modeling of RNA
Seq data for isoform discovery and abundance estimation SLIDE [46], used a sparsecodinglike
approach to predict the likely position of isoform given RNAseq data.
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Figure 2.1: Architecture of Standard Autoencoder.

Deep Learning based representation learning methods

Usually, we call a model “deep”, when the model is trying to model a function with an explicit
nested structure. A neural network with more than one hidden layer is considered as a deep model,
which gave birth to the popular idea of “deep learning”. The renaissance of deep learning from 2006
began with the discovery that, greedy layerwise unsupervised pretraining can be used to find a good
initialization for a joint learning procedure over all the layers [47, 48]. Moreover, the same approach
has been used to train even fully connected architectures successfully. Essentially, each layer of such
hierarchical structure is to learn intermediatelevel features. Empirically, it has been observed exten
sively in many studies [49], the stacking of intermediate features often yields better representations.
Due to the extreme popularity of deep learning in recent years, there have been extensive approaches
proposed, here I focus on only the autoencoders, a wellestablished technique to learn an encoding
function that maps a highdimensional vector to a lowdimensional embedding.
Overview of Autoencoders

An autoencoder [50] is a neural network that is trained to learn how copy its input to output.
Typically, it has at least one hidden (intermediate) layer that represents the input with certain codes.
A framework for autoencoder with only one hidden layer h is shown in Figure 2.1, In its simplest
sense, the autoenoder network can be considered as consisting of two parts: an encoder function f
that generates the hidden code for the input, i.e., z = f (x) and a decoder function g that produces the

Chapter 2: Method Review

17

output (reconstructed input), i.e., r = g(z). We often call encoder and decoder function as encoder
module and decoder module respectively, since they can be modeled with any neural network archi
tecture themselves. It is easy to see that the reconstructed input can be represented by a nested func
tion as r = g(f (x)) . As mentioned above, the purpose for autoencoder is to make the reconstructed
input as similar as possible to the original input (maximize similarity) or, in practice to minimize the
reconstruction loss (minimize difference). In most of cases, learning objective can be represented as
to minimize,

1X
L(x, r)
n

(2.11)

“Distance” (or “Dissimilarity”) measurements like MSE (mean squared error, used for continuous
valued input), crossentropy (used for binary valued input) are the commonly used loss functions.
Autoencoders are considered as a special case of feedforward networks with an unsupervised objec
tive, thus can be trained with the common techniques applicable to feedforward networks learning.
However, copying input to output essentially is not an interesting or challenging task. For ex
ample, if we make f and g inverse functions of each other, then such autoencoder will be able to
achieve exact reconstruction even. In such cases, the autoencoders are not necessarily useful, since
the hidden code doesn’t have to learn the inherent structure underlying the data to get the reconstruc
tion done. So, more than often, autoencoders are designed to be unable to learn to copy perfectly,
while instead encourage the intermediate codes learned to capture the hidden patterns of the input.
Typically, such autoencoders are restricted in different forms and can be called regularized autoen
coders.
In the early days, autoencoders were primarily used as dimension reduction technique, to learn
an undercomplete representation, where the dimension of the hidden code is specified to be smaller
than the dimension of the input data. In this setting, the dimensionality of the hidden code is used as
the regularization on the autoencoder (called undercomplete autoencoder). A special example of the
undercomplete autoencoder is one that only linear activation functions are allowed for the encoder
and decoder with the mean squared error being used as the loss function (reconstruction loss). The
representation learned from such autoencoder will span the same subspace as standard PCA, and
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such autoencoder is no different from the standard PCA. The undercomplete autoencoder is just
one example of regularized autoencoders. More often, other forms of regularization are included to
explicitly push learned hidden representation towards spefic desired properties as well as ensure the
generalization of autoencoders.
Deterministic Autoencoders

Autoencoders as described above, hidden codes are learned though a fixed mapping defined
by encoder network. Such autoencoders are called deterministic autoencoders. Depending on the
choice of regularization techniques employed, deterministic autoencoders can be further split into the
following categories.
Sparse Autoencoders A sparse autoencoder is an autoencoder whose training objective in

cludes a sparsity penalty (Ω(z)) on the hidden code, in addition to the reconstruction cost.

1X
L(x, r) + Ω(z)
n

(2.12)

Commonly used sparsity penalty terms include L1norm [51, 52], Studentt penalty (log(1+ z2j ))[53].
Adding such sparsity penalty intuitively can ensure that only a few input configurations have low
loss. In addition to considering the sparsity penalty as a regularizer for reconstruction task, we could
also think sparse autoencoders from the probabilistic modeling perspective as mentioned in chapter
two, where the hidden codes to be learned is the latent variables that serve as the underlying explana
tory factors of the realizations of the observed variables. Formally, we can represent the entire sparse
autoencoder as a generative model, and the likelihood of such model can be shown as below,
Z

Pmodel (x) =

Pmodel (x|z)Pmodel (z)dz =

Z

Pmodel (x, z)

(2.13)

where x is a vector of observed variables in space X ∈ Rd and z is the vector of latent variables in
the space Z ∈ Rq , and Pmodel (z) is the model’s prior distribution over the latent variables that repre
sents the model’s belief or assumption. Autoencoder can thus be considered as approximating such
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likelihood with a point estimate for one highly likely value for z. But different from sparse coding
model, z will be the output of the parametric encoder rather than the result of an optimization that
aims to infer the MAP value of z. Further, in the context of sparse autoencoder, Pmodel (z) needs to
be sparsityinducing, for example, the Laplace prior or Studentt prior.
Contractive Autoencoders The contractive autoencoder (CAE) [54] introduces another type of

constraint on the hidden code to push the derivatives of encoder function to be as small as possible,
so that hidden codes capable of resisting input perturbations can be learned. The objective function
can be represented as,

1X
L(x, r) + Ω(h)
n
where Ω(h) = λ

∂f (x) 2
.
∂x
F

(2.14)

The penalty Ω(h) the squared Frobenius norm of the Jacobian matrix

of partial derivatives associated with the encoder function. The goal of contractive autoencoders is
to make the encoder to resist infinitesimal perturbations of the input while not sacrificing too much
in terms of the reconstruction loss, so that the hidden codes learned could potentially capture more
of the inherent patterns underlying the input data. By doing so, CAE is encouraged to map a local
neighborhood of input points to a smaller neighborhood of output points (input reconstructions), as
the name suggests – contracting neighborhoods. The learned representations can be thought of as a
manifold structure of the data, where the directions of observed variables leading in large changes in
latent variables could approximately correspond to the tangent planes of a manifold.
Two practical issues with CAEs need to be pointed out, though. Firstly, although it is relatively
cheap to compute the contractive penalty when the encoder network only includes one single hidden
layer, computation will become significantly higher when the encoder network becomes deeper. One
solution proposed in [54] is to separately train a series of single layer autoencoders instead train all
layers at the same time. Each of them is trained to reconstruct the output of the previous autoencoder.
Then the composition of the autoencoders is used as the final model. Yet this model is not the same
as what would be obtained by jointly training the entire deep architecture with a penalty on the Jaco
bian of a deep encoder network. Secondly, there have to be some capacity constraints on the decoder
network, such as tying the parameters of encoder and decoder network. Otherwise, the decoder could
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potentially adapt to compensate the contractive regularization on the encoder network and result in
useless hidden representation being learned.
Denoising Autoencoders Rather than adding penalty terms to the cost functions, denoising

autoencoder attempts to minimize the reconstruction cost with the input corrupted by some form of
noise [55]. The goal of denoising autoencoders is to make the reconstruction function resist small but
finitesized perturbations of the input. Denoising autoencoders (DAE) thus have to be able to undo
the corruption rather than copy their corrupted input. In other words, the encoder and decoder are
forced to learn the structure of the distribution of input data implicitly. The learning objective can be
represented as follows,

1X
L(x, f (g(xe)))
n

(2.15)

where xe is the corrupted input. From a probabilistic modeling perspective, DAE aims to learn a re
construction distribution Preconstruct (x|xe) = Pdecoder (x|f (xe)) estimated from training pairs (x, xe),
where xe follow certain corruption process and Pdecoder defined by the decoder network. Thus, we can
further view DAE as performing maximum likelihood learning of Pdecoder (x|f (xe)). Besides max
imum likelihood optimization, score matching [56] can also be used as an alternative approach to
train DAE model, where probability distributions are estimated by encouraging the model to have
same scores as the data distribution (empirical distribution of the data) at every training data point.
Specifically, for DAE training, the score to be used is ∇x logP (x). DAEs are also an example of how
overcomplete, highcapacity models may be used as autoencoders so long as care is taken to prevent
them from learning the identity function.
Stochastic Autoencoders

Different from deterministic autoencoders, where the hidden representations are learned via
the fixed mapping defined by the encoder network from the raw input, modern autoencoders have
generalized the idea of an encoder and a decoder from deterministic functions to stochastic mappings.
With respect to the formation of stochastic autoencoder, its encoder network can parametrize an en
coding distribution Pencoder (z|x), from which we can sample hidden codes given an observation of x.
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Figure 2.2: Architecture of Stochastic Autoencoder.

Similarly, the decoder network is used to parametrize a decoding distribution of Pdecoder (x|z). Then
given a hidden code z, with prior z ∼ P (z), we could train the entire autoencoder by maximizing
the marginal likelihood (loglikelihood) of the training data. A general framework of the stochastic
autoencoder is shown in Figure 2.2, In this setting, to obtain the latent representation given observa
tions, an inference process is needed, or true posterior P (z|x) needs to be estimated. By Bayes rules,
we can get,

P (z|x) =

P (x|z)P (z)
P (x)

Thus, to get the inference from observed variables to latent variable, P (x) =

(2.16)
R

P (x|z)P (z)dz needs

to be calculated, however, it is easy to see that this integral requires exponential time to compute
since it needs to be evaluated over all configurations of latent variables. Thus, efficient approxima
tion of posterior needs to be done.
Variational Autoencoders Variational inference approximates the true posterior with a fam

ily of parametric distributions with KullbackLeibler divergence (KL divergence) used as the mea
surement of the approximation quality. And the optimal approximate posterior is the one that mini
mizes the KLdivergence from true posterior P (z|x). Variational autoencoder (VAE) [40] adopted
this idea and proposed to use a network architecture to parametrize such approximate posterior (i.e.,

Pencoder (z|x)). The KL divergence between approximate posterior and groundtruth posterior is
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given below,

DKL (Pencoder (z|x)||P (z|x)) = Ez∼Pencoder (z|x) [logPencoder (z|x) − logP (z|x)]
= Ez∼Pencoder (z|x) [logPencoder (z|x) − logP (x|z) − logP (z)] + logP (x)
(2.17)
we can get,

logP (x) − DKL (Pencoder (z|x)||P (z|x)) = Ez∼Pencoder (z|x) [logP (x|z) + logP (z) − logPencoder (z|x)]
(2.18)
Up to this point, the lefthand side of above equation is the quantity to be maximized, including the
maximization of the marginal likelihood of observation as well as the minimization of nonnegative
KLdivergence between true posterior and approximate posterior. The righthand side can be fur
ther reduced to Ez∼Pencoder (z|x) [logP (x|z)] − DKL (Pencoder (z|x)||P (z)), which is a tractable quan
tity and can be optimized via standard stochastic gradient descent. It is also called ELBO (Evidence
Lower BOund) and used as the training objective of variational autoencoders, denoted here as LV AE .
Specifically, P (z) is the prior over latent variables, typically z ∼ N(z; 0, I). P (x|z) can be mod
eled by the decoder (i.e., Pdecoder (x|z)). Depending on the characteristics of input data, it could be
assumed to follow different known distributions, such as Gaussian distribution for continuousvalued
data, and Bernoulli distribution for binaryvalued data. As for Pencoder (z|x), the usual choice is

N(µ, Σ), where µ, Σ are to be determined by the encoder network, and Σ is normally constrained
to be a diagonal matrix. The parameters of both encoder and decoder network can be learned by max
imizing the ELBO. In practice, the reparametrization trick is also employed to ensure the stochas
ticity of the model while keeping gradient descent applicable in the training process. The variational
autoencoder is theoretically elegant and capable of achieving stateoftheart generative modeling
result [57]. Moreover, it is very simple and straightforward to implement and supports a wide range
of extensions. Notable examples include importance weighted variational autoencoder [58], β VAE
[59], Factor VAE [60], and InfoVAE [61].
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Adversarial Autoencoders Adversarial autoencoders (AAE) [62] is another type of stochastic

autoencoder which incorporates generative adversarial networks (GAN) [63] to perform variational
inference by matching the aggregated posterior of the hidden code vector of the autoencoder with an
arbitrary prior distribution. In the framework of standard generative adversarial network, a minmax
adversarial game is established between two neural nets – a generator network G and a discrimina
tor network D. The network D aims to distinguish samples of training data (x ∼ Pdata ) from the
samples produced by the generator network G from ẑ ∼ P (ẑ), while generator network G tries to
confuse discriminator D as much as possible by imitating the true data. The solution to this game
can be formally expressed as

minG maxD Ex∼Pdata [logD(x)] + Eẑ∼P (ẑ) [log(1 − D(G(ẑ)))]

(2.19)

In AAE, the encoder network is used as the generator to make hidden codes (z) mapped from the
input (x ∼ Pdata ) as similar as possible to ẑ ∼ P (ẑ), here P (ẑ) stands for the prior distribution
we desire to impose on the codes. The encoder of AAE Pencoder (z|x) is used to define an aggregated
posterior distribution of Pencoder (z) on the hidden codes as follows:
Z

pencoder (z) =

Pencoder (z|x) Pdata (x)

(2.20)

The adversarial autoencoder is regularized by matching Pencoder (z) to P (ẑ). Similar to original
GAN, the training of AAE needs to be done alternatively between the reconstruction loss and dis
criminator loss. Here, Pencoder (z|x) can be assumed to be deterministic mapping of observations
as standard autoencoder as well as follow a Gaussian distribution as in VAE where the same re
parametrization trick needs to be employed. A brief architecture of AAE is given in Figure 2.3,
Similar to AAE, adversarial regularized autoencoders (ARAE) [64] also includes a GAN mod
ule in the architecture. From Figure 2.4, different from AAE, a complete GAN architecture is incor
porated in ARAE. In ARAE, the hidden codes mapped from the input data via encoder network are
used as the positive samples to the GAN module. In contrast to AAE, the training of ARAE also in
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Figure 2.3: Architecture of Adversarial Autoencoder.

Figure 2.4: Architecture of Adversarial Regularized Autoencoder.

cludes the generator that maps random noise ẑ ∼ N(ẑ; 0, I) to approximate the hidden codes of
autoencoder.
When it comes to applications of autoencoderbased representation learning in biomedical
studies, to deal with the highdimensionality concern of the omics data, apparently, undercomplete
autoencoder is an obvious choice. Besides the highdimensionality concern, the reliability of cross
experiment datasets is limited by the technical noise and unmatched experimental conditions. Of
ten, denoising and enhancement of the available data are necessary. A useful tool for this scenario is
denoising autoencoders. In [65], stacked denoising autoencoders (SDA) are applied to detect func
tional features from the cancer gene expression profile. [11] presented an unsupervised approach
that effectively applied SDA to capture key biological principles in breast cancer data. [66] further
improved ADAGE to extract both clinical and molecular features successfully. To build better signa
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tures that are more consistent with biological pathways and enhance model robustness, an ensemble
ADAGE [67] was proposed to integrate stable signatures across models. Besides, [68] first utilized
multilayer denoising autoencoders to enhance yeast expression microarray data, and then success
fully identified cell cycle process through a following clustering task. [69] proposed a fourlayered
autoencoder network with sparsity regularization, in which each layer is accounting for a specific bio
logical process in gene expression to explicitly model the hierarchical organization of transcriptomic
machinery. Recent works focused more on the application of variational autoencoders, which seems
more promising at capturing the internal dependencies among data. [70] trained VAEbased models
to reveal the underlying patterns in the pathways of gene expression and compared their three VAE
architectures to other dimensionality reduction techniques. The same group of authors later proposed
[71], when they trained a VAE on The Cancer Genome Atlas (TCGA) pancancer RNAseq data to
uncover biologicallyrelevant features. [72] introduced the DeepProfile, a framework featuring VAE,
to extract latent variables that are predictive for acute myeloid leukemia from expression data. [73]
proposed Deep Genomic Signature (DGS), a pair of VAEs that are trained over unlabeled and labeled
data separately from expression data for predicting metastasis.
To sum up, miscellaneous unsupervised representation learning approaches have been pro
posed. Yet, it remains an open question to pick the best overall unsupervised representation learning.
To put them into practice, innovative adaptations tailored to specific datasets and problems at hand
are still much needed.

Overview of Feature Based Domain Adaptation

Although supervised learning is arguably the most popular type of machine learning and has
enjoyed success across diverse application areas, the majority of them rely on one common assump
tion: the training and testing data are drawn from the same distribution. When the assumption is vio
lated, the model will experience a performance decline due to the domain differences. Domain adap
tation methods are thus proposed to alleviate this dilemma. Specifically, domain adaptation aims at
transferring the knowledge a trained predictive model has gained on one data domain with sufficient
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labeled data to another data domain without or with limited labeled data. Here, a data domain can be
denoted as D as D = {X , P (X)}, where X stands for the feature space and samples within domain

D, X = {x1 , . . . , xn } ∈ X . P (X) is the affiliated marginal distribution. In the classical setting of
domain adaptation, we consider two domains, namely source domain DS = {Xs , Ps (Xs )} and target
domain Dt = {Xt , Pt (Xt )}. And there are abundant labeled samples from source domain for one
common predictive task τ of interests, while only limited or none labeled sample of target domain
for the same task. The ultimate goal is to perform accurate predictive task of interest τ based on tar
get domain data, by transferring knowledge possessed in source domain labeled data. Because of its
ability to adapt labeled data for use in a new application, domain adaptation can reduce the need for
costly labeled data in the target domain.
Most of recent domain adaptation methods align source and target domains by creating a do
main invariant feature representation, typically in the form of a feature extractor neural network.
A feature representation is considered domain invariant if the features follow the same distribution
regardless of the data from the source or target domain. These models generally assume the exis
tence of such feature space and the marginal label distributions of task τ do not differ significantly
among the domains. Given a predictor performs well with the domain invariant features in the source
domain, the same predictor is expected to generalize well in the target domain. A general invariant
feature based domain adaptation learning framework is shown in Figure 2.5. Under this framework,
samples from both domains in their respective feature space first go through a feature encoder net
work. The feature encoder networks for different domains could share weights, share similar regu
larization or nonrelated. Then via additional feature alignment component, encoded features from
boths domain are further aligned to be domaininvariant. From the learnt domain invariant feature,
additional task predictor is trained with source domain labeled ata to maintain this trait space’s dis
criminative power for specific tasks. In addition to choices made on weight/regularization sharing
for domain feature encoders, methods generally differ in the design of feature alignment component.
In particular, it could be either in the form of distribution discrepancy measurement minimization,
adversarial or reconstruction training optimization.
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Figure 2.5: General framework for featurebased domain adaptation methods.

Discrepancybased domain invariant feature learning

Common choices for distribution discrepancy measurement include maximum mean discrep
ancy, correlation alignment, and Wasserstein distance.
Maximum Mean Discrepancy Maximum Mean Discrepancy (MMD) ([74]) is a distance mea

sure between distributions P (X) and Q(Y ) which is defined as the squared distance between their
embeddings in the RKHS (Reproducing Kernel Hilbert Space, [75]). Given Nx samples from P (X),
and Ny samples from Q(Y ), one can approximate MMD empirically via the below formula,
Ny
Ny
Nx
Nx X
2 X
1 X
1 X
(i)
(j)
(i) (j)
κ(x , x ) −
κ(y (i) , y (j) ) (2.21)
LM M D (P, Q) = 2
κ(x , y ) + 2
Nx i,j=1
Nx Ny i=1 j=1
Ny i,j=1

where κ is a PSD kernel function. It can be proven that MMD is zero if and only if the two distribu
tions are equal. Deep domain confusion network [76], originally designed for classification task for
unlabeled target domain images, as shown in Figure 2.6, adopts weight sharing feature encoder (as
stacked convolution and fullconnected layers) across labeled source and unlabeled target domains,
and trains the whole network via a weighted combination of MMD distance between source and tar
get domain encoded features and classification loss to achieve domain transfer. Moreover, multiple
kernel variant of MMD (MKMMD) and joint MMD were investigated in [77] and [78] respectively.
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Figure 2.6: Architecture of Deep Domain Confusion network. Figure appeared in [76].

CORrelation ALignment CORrelation ALignment (CORAL) [79] aligns the input feature

space of the source and target domains by minimizing the difference between their secondorder
statistics. To achieve such minimization, in the original CORAL [79], a linear transformation A is
applied to the original features and use the Frobenius norm as the matrix distance metric,

minA AT Cs A − Ct

2
F

(2.22)

where Cs and Ct are the covariance matrices for source and target features respectively. Later, it
was extended to work with deep neural network [80], where CORAL loss is similarly formulated as
above among encoded features of source and target domain samples. And the overall architecture
is similar to the architecture of DDC [76] in Figure 2.6, the only difference is that Deep CORAL
employs CORAL loss in place of the MMD loss and trains the whole network via a weighted combi
nation of CORAL loss and supervised loss.
Wasserstein Distance Wasserstein Distance originates from a problem know as ”optimal trans
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port”, where resource allocation such as finding an optimal way to move materials from mines to
factories are studied. If the moving cost is a norm, then the solution to a discrete optimal transport
problem can be used a discrepancy measurement between distributions. Joint distribution optimal
transport (JDOT) [81] and its neural network extension DeepJDOT [82] were proposed with such
realization. The overall architecture used by DeepJDOT is also similar to the one used in DDC[76],
while the dicrepancy is measured with the Wasserstein distances shown below,

∥Hs − Ht ∥2

(2.23)

where Hs and Ht stand for the encoded features through a shared feature encoder of source and tar
get samples respectively.

Adversarial training based domain invariant feature learning

Most of methods belonging to this category employs a domain classification module in the
feature alignment component. The domain classification module aims to distinguish samples from
source domain from target domain, while the feature extractors aims to generate features that can
confuse this domain classification module into wrong prediction. A minmax game is formulated
between the them to learn the domain invariant features. In domain adversarial neural network
(DANN, [83]), as shown in Figure 2.7. A shared feature extractor is adopted, and the domain classi

Figure 2.7: Architecture of Domain Adversarial Neural Network. Figure appeared in [83]
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Figure 2.8: Architecture of Adversarial Discriminative Domain Adaptation. Figure appeared in [84]

fier outputs the binary domain label (namely, source or target domain) based on the encoded features.
DANN inserts a gradient reversal layer between the feature encoder and domain classifier, which
will negate the domain classification loss gradient sent to feature encoder in the backpropagation
process. DANN attempts to learn the feature encoder that maps the original samples from both
domains into a feature space that allows accurate task prediction performance with labeled source
samples, while cripples the ability of domain classifier to precisely distinguish samples from source
domain to target domain in the form of binary cross entropy.
In adversarial discriminative domain adaptation neural networks (ADAA, [84]), as shown in
Figure 2.8. ADAA splits the overall training process into three steps, namely pretraining, adversar
ial adaptation and testing. During the pretraining, a feature encoder and task predictor are trained
for source domain labeled sample with the supervised task. Then, in the adversarial adaptation step,
a generative adversarial neural network [85] is incorporated. The feature encoder for the target do
main samples are trained such that the discrimator of GAN cannot reliably distinguish the encoded
features from their domain origin. In the final testing step, the trained target feature encoder and the
task predictor in combination are used to complete the inference step.
Moreover, WDGRL [86], Wassertein distance guided representation learning for domain adap
tation, replaced domain classifier with a Wassertein Generative Adversarial Network [87] to learn the
domain invariant features.
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Figure 2.9: Architecture eof Domain Separation Network. Figure appeared in [89]

Reconstruction based domain invariant feature learning

Reconstruction based domain invariant feature feature learning was proposed under the as
sumption that feature alignment can be achieved by learning a representation that can be used to re
construct target domain samples [88] or both the source and target domain data [89], as well as sup
port predictive modeling of label source domain samples. These methods incorporate autoencoder
components for the reconstruction of input samples. Representative works include deep reconstruc
tion classification network [88], marginalized denoising autoencoder [90], multitask autoencoders
[91]. Moreover, domain separation network [89] was proposed to explicitly split domainspecific pri
vate representations and domaininvariant shared representation. Its architecture is shown in Figure
2.9. The shared feature encoder aims to learn shared representation that contains common transfer
able information while private encoders learn the domainspecific private representation. The con
catenations of private and representations are expected to complete the reconstruction task. And the
private and shared representations of each individual domain are pushed apart with a soft orthogonal
ity loss. Shared representations across domains are further trained with discrepancy minimization or
adversarial training objective in addition to shared feature encoder network. Further shared represen
tation of labeled source domain samples are further adapted to possess predictive power of tasks of
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interests.
In summary, the aforementioned featurebased domain adaptation methods offer various
approaches that can be utilized to transfer knowledge from one domain to another. Given proper
biomedical datasets and understanding of fundamental relationship between different data entities,
they can be adopted to encourage biological meaningful representation learning.
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Chapter 3
Comparative Study of Autoencoders

Introduction

Due to the heterogeneity among cell lines (tumors), the accurate prediction of drug response
over cell lines (tumors) remains a challenging task. Pharmacogenomics [92] is a field that studys
how genomic alternations and transcriptomics affect drug. In this benchmark study, we aim to uti
lize the transcriptomic profiles of cell line samples to predict individual drug responses. The drug
sensitivity data as well as cell lines transciptomic profiles can be obtained from public pharmacoge
nomics data repository, such as Cancer Cell Line Encyclopedia (CCLE, [15]), and GDSC [93, 94].
However, with only hundreds of available labeled samples, obviously, it is very difficult to build a
generalizable model capable of generating accurate predictions of drug responses. We seek effective
ways to leverage more available unlabeled transcriptomics dataset. In particular, in this benchmark
study, we aims to compare the various autoencoders’ performance (reviewed in Chapter 2) in terms
of their effectiveness in assisting drugsensitivity prediction task. The overall training paradigm of
this benchmark study is shown in Figure 3.1.

Experiment Setup

As mentioned above, the drugsensitivity data were obtained from GDSC [93, 94], and cell
lines transciptomic profiles were downloaded from Cancer Cell Line Encyclopedia (CCLE, [15]).
After missing value imputation, we collected a dataset consists of drug sensitivity scores (real
valued) of 610 cell lines against 205 drugs. For additional unlabeled transcriptomic profiles (gene
expression), we downloaded cancer patient tumor sample gene expression data from the Cancer
Genome Atlas (TCGA, [95]). Firstly, we converted the normalized FPKM gene expression values
through log2 transformation, then genes with low information burden (mean value < 1 or standard
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Figure 3.1: The autoencoder benchmark study training includes two steps: 1)Pretrain the encoder with
autoencoder reconstruction task using unlabeled data. 2)Finetune the encoder and appended regressor network
with supervised drug response prediction task using labeled data.

deviation < 0.5) were filtered out. Further, we selected 5000 genes with the highest variability
meansured by median absolute deviation (MAD) as the raw input features. In total, we have 11351
gene expression samples (including 10332 TCGA sample, and 1019 CCLE cell line samples of
which 610 are with labels). We adopted pretraining finetuning procedure as shown in Figure 3.1,
in pretraining, we trained the encoder with unlabeled transciptomics data, and during finetuning,
additional regressor module were appended after pretrained encoders to complete drug sensitivity
prediction task. All autoencoders shared the exactly the same architecture [1024, 512, 256, 128, 256,
512, 1024], and the hidden dimension is specified as 128. Appended regressor network shares the
same architecture [128,128] with the number of output units set as the same as number of drugs in
consideration (i.e. 205).

Result & Discussion

Since our primary goal in this benchmark study is to compare the efficacy of different autoen
coders in this drug response prediction task, we designed the following metric as the final measure
ment. For any given drugcell line pair, we will rank predictions from different autoencoders based
on their absolute value difference from the ground truth value. And the autoencoder obtained the
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smallest difference will be ranked first, and so on so forth. As our final result, we will demonstrate
the percentages of different autoencoder acquired in the top three ranks. The result is listed in Table
3.1.

Method
Standard AE
DAE (Gaussian Noise)
DAE (Missing)
CAE
VAE
betaVAE
InfoVAE
ARAE
Stacked DAE

RANK1
14.82%
18.18%
17.11%
0.99%
18.01%
10.94%
9.85%
1.98%
8.11%

RANK2
13.03%
19.06%
16.95%
1.93%
17.08%
10.04%
10.96%
2.99%
7.98%

RANK3
11.97%
17.86%
16.21%
7.04%
15.87%
10.13%
10.09%
2.87%
7.97%

Table 3.1: Benchmark Performance Comparison among Autoencoders

As seen from our autoencoder comparison benchmark study results, it is hard to draw concrete
conclusions which architecture is superior to others. And even more interestingly, two of the variants
of popular variational autoencoders, betaVAE and infoVAE cannot beat its original versions or even
standard autoencoder in the drugresponse task given in our study. It may be due to that betaVAE
and infoVAE are primarily designed for the representation disentanglement. while genegene inter
actions are essential characteristics of a biological system, and critical for drug responses. In certain
sense, the results demonstrated the difficulty in applying such new deep models in biological studies
domain. Without any doubt, to properly leverage the strength of popular deep modelbased represen
tation learning methods in omics data studies remains a challenging task, considering the fact that
we only have limited abilities to interpret the biological information compared to other fields, such
as vision, audio, and language processing, as well as the endeavor involved to tune a deep model. To
fully realize its potential and further drive the constant progress in biomedical studies, innovations
such as a more efficient learning scheme or new network architectures based on biologically inspired
inductive bias are still in much needs.
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Chapter 4
CrossLEvel Information Transmission (CLEIT) network

Introduction

Advances in nextgeneration sequencing have generated abundant and diverse omics data.
They provide us with unparalleled opportunities to reveal the secrets of biology. An unsolved prob
lem in biology is how to predict observable traits (phenotypes) given a new genetic constitution
(genotype) under environmental perturbations. The predictive modeling of genotypephenotype as
sociations will answer not only fundamental questions in biology but also address urgent needs in
biomedicine. A typical application is anticancer personalized medicine. Given a new cancer pa
tient’s genetic information, what is the best existing drug to treat this patient? It is different from
GenomeWide Association Study (GWAS) and Transcriptome Wide Association Study (TWAS),
whose goal is to identify statistical correlations between observed genotype and phenotype. Predict
ing phenotype from a new genotype is challenging due to the asymmetrical multilevel hierarchical
organization of the biological system. Cell, tissue, and organismlevel phenotypes do not arise di
rectly from DNAs but hierarchically through multiple intermediate molecular or cellular phenotypes
characterized by protein interactions, gene expressions, etc. [96], as illustrated in Figure 4.1. In other
words, in the information transmission process from DNA to RNA to protein to a biological pathway
to the observed phenotype of interest, the higherlevel features (e.g., gene expression) usually have
stronger discriminative and interpretable power than the lower level features (e.g., somatic muta
tion) in a supervised learning task for predicting the phenotype, which is independent on the machine
learning model applied. This premise is supported by multiple studies such as anticancer drug sen
sitivity prediction [97], cancer drug combination [98], microbiome [99], and empirical studies [100].
Therefore, a multilevel approach is needed to simulate the asymmetrical hierarchical information
transmission process for linking the genotype to the phenotype [101], which will, in turn, improve
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Figure 4.1: Rationale of CLEIT. Cellular phenotypes rise from genotypes via multilevel intermediate
molecular types hierarchically from DNA to RNA to protein to biological pathway (blue arrows). The
predictive and interpretable power of the DNAlevel features for the phenotype is weaker than that of the
highlevel features such as transcriptome and biological pathways. Instead of predicting the phenotype from
the genotype directly by bypassing the intermediate molecular types (gray dashed arrow), we will include the
information of intermediate molecular type and model the hierarchical organization of a biology system
(orange solid arrows).

the interpretability of model predictions and facilitate clinical decisions. The interpretability of ma
chine learning model is critical for the biomedical application. In principle, the multiscale modeling
of genotypephenotype associations will facilitate opening the black box of machine learning [102].
For example, the embedding from the transcriptomics profile, directly or indirectly, can be used to
elucidate biological pathways responsible for the synergy of drug combinations [103]. In addition
to the above fundamental challenge, the predictive modeling of genotypephenotype associations
faces several technical difficulties that hinder the application of existing machine learning methods.
Firstly, omics data are often in an extremely high dimension. Secondly, the coherently labeled data
are scarce compared with unlabeled data. Finally, it is not a trivial task to integrate heterogeneous
omics data from different resources and modalities.
We develop a novel neural networkbased framework: CrossLEvel Information Transmis
sion (CLEIT) network to address the aforementioned challenges. Inspired by domain adaptation
techniques, CLEIT first learns to construct the lowdimensional latent representation that encodes
signals indicative of tasks at hand from a highlevel domain. Then, CLEIT uses the embedding from
the highlevel domain as groundtruth embedding to regularize the representation learning of the
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lowlevel domain in the form of a contrastive loss. In addition, we adopt a pretrainingfinetuning
approach, where pretraining enables the usage of unlabeled heterogeneous omics data to improve
the generalizability of CLEIT, while finetuning is employed to enable more taskfocused predictions
given a specific labeled dataset.
As a demonstration of CLEIT’s efficacy in a biological setting, we applied CLEIT to predict
ing anticancer drug sensitivity from somatic mutations. Precision anticancer therapy tailed to indi
vidual patients based on their genetic profile has gained tremendous interest in clinical [104]. Exist
ing studies such as [105], [106] focused on inferring drug response based on most salient mutation
gene signatures. Although the drug response of several successful targeted therapies, e.g., kinase
inhibitors, can be predicted from a few driver mutations harbored in patients, the percentage of US
patients who can benefit from the targeted therapy is only about 4.9% [107]. The choice of optimal
therapy for most cancer patients remains a significant challenge [108]. It is well known that cancer
acquires numerous mutations during its somatic evolution. Both driver and passenger mutations col
lectively confer cancer phenotypes and are associated with drug responses [109]. Thus it is necessary
to use the entire mutation profile of cancer to predict anticancer drug sensitivity in most cases. The
machine learning models that can explicitly model hierarchical biological processes will undoubtedly
facilitate the development of personalized medicine. Our extensive experiments show that CLEIT
significantly outperforms other stateoftheart methods in this regard.

Related Works

CLEIT aims to develop a framework that constructs an indicative knowledgeabundant low
dimensional latent space from a high dimensional feature space of particular domains, which lacks
salient discriminative information of tasks of interest. For example, although somatic mutation data
undoubtedly posses biologyrich information, its sparsity and binary characteristics often make it
extremely challenging to be utilized to build effective machine learning models for downstream pre
dictive tasks. To combat such data limitation issues, we seek to transfer knowledge from other levels
of omics data to regularize the learning of mutation data training. If we treated different levels of
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multiomics data as from different data domains, we could incorporate domain adaptationinsipred
strategies to encourage the knowledge transfer from one to another. In particular, we explored the
featurebased domain adaptation techniques as detailed in Chapter 2.
To be noted, the multimodal integration of somatic mutation and gene expression data has
been utilized to improve predicting anticancer drug sensitivity, e.g., in [97] and [110]. These meth
ods assume that both labeled mutation data and labeled gene expression data are available during
training and inference. Additionally, they integrate omics data horizontally. In contrast, CLEIT only
needs to use the mutation data as the input during the inference stage. During the training stage, the
mutation and gene expression data can come from different data resources and be unlabelled. Thus,
CLEIT is more practical than existing methods. Moreover, CLEIT explicitly models the hierarchical,
asymmetrical information transmission in a biological system, as shown in Figure 4.1.

Contributions

CLEIT aims to address an important problem of multiscale modeling of genotypephenotype
associations. Although CLEIT borrowed some ideas from the domain adaptive transfer learning,
there is a significant difference between CLEIT and those approaches. The goal of classic domain
adaptation is to use the label information from the source domain data to boost the performance of
supervised tasks in the target domain without abundant labels. The feature in the target domain usu
ally has a similar discriminative power to that in the source domain. While in our case, we focus on
resolving the inherent discriminative power discrepancy between two hierarchical related domains.
The feature of the highlevel domain has higher discriminative power than that of the lowlevel do
main. Moreover, the entity types of source and target domains are usually the same in conventional
domain adaptation. In our case, they are of different types. Specifically, our goal for information
transmission is to solely push the latent representation of the lowlevel domain to approximate the
one of the highlevel domain; that is, the feature representation learned from the highlevel domain
is fixed and used as groundtruth feature representation of the lowlevel domain. In this setting, the
latent space where the crosslevel information transmission happened is no longer a symmetrical
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consensus from different domains. The highlevel and lowlevel domain is used as an input and an
output, respectively, to boost the discrimination power of the lowlevel domain. A mapping function
is learned between them.
The major contributions of this research are summarized as follows.
 We propose a novel neural network framework that can explicitly model asymmetrical cross
level information transmissions in a complex system to boost the discriminative power of the low
level domain. The multilevel hierarchical structure is the fundamental characteristic of the biologi
cal and ecological system. The proposed architecture is general and can be applied to model various
machine learning tasks in a multilevel system.
 The proposed neural network framework provides a new approach to integrating multiple
omics data vertically to represent the multilevel organization of a biological system.
 We design a pretrainingfinetuning strategy to fully utilize both labeled and unlabeled omics
data that are naturally noisy, highdimensional, heterogeneous, and sparse.
 In terms of biomedical application, the CLEIT model significantly improves personalized
anticancer drug sensitivity prediction using only somatic mutation data. To the best of our knowl
edge, CLEIT is the first deep learningbased framework designed to perform drug sensitivity pre
diction tasks solely on wholegenome somatic mutation profiles, which achieves comparable perfor
mance to the model trained from gene expression profiles. The oncology panel of somatic mutations
has been routinely performed in cancer treatment. The application of CLEIT may improve the effec
tiveness of cancer treatment and achieve personalized medicine.

Method
Problem formulation

We denote a data domain D as D = {X , P (X)}, where X stands for the feature space and
samples within domain D, X = {x1 , . . . , xn } ∈ X . P (X) is the affiliated marginal distribution.
In this work, we consider two domains DH = {Xh , Ph (Xh )} and DL = {Xl , Pl (Xl )}, namely
the highlevel domain and lowlevel domain, where Xh ̸= Xl , Ph (Xh ) ̸= Pl (Xl ). In addition, one
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Figure 4.2: CLEIT Framework. The training of CLEIT involves five steps. First, the encoder of DH is
learned from an autoencoder and finetuned by a supervised multitask MLP in steps 1 and 2. Then, the
embedding of DL is encoded from an autoencoder in step 3, and the difference between it and that of DH is
minimized via an MLP transmitter in step 4 as measured by contrastive loss. In step 5, the supervised model of
DL is finetuned by the model that appends the pretrained multitask MLP of DH in step 2 and the
regularized encoder of DL in step 3.

common task τ of interest is to predict phenotype or other outcomes. This task can be done individu
ally from both domains but with different performance, where DH can achieve superior performance
to DL independent on machine learning models applied to them. Here, the performance difference
is due to the nature of each domain, instead of the volume of labeled samples as in a classical do
main adaptation setting. However, although feature space Xh and Xl are not the same, the entities
cross the feature spaces are hierarchically related, such as the multilevel hierarchical organization of
omics data of a biological system. Based on this realization, this work aims to utilize the knowledge
learned from DH to boost the predictive power of DL .
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CLEIT framework

To use the knowledge learned from DH to boost the performance of DL , we propose a Cross
LEvelInformation Transmission (CLEIT) framework. The strategy of CLEIT is to encode the data
from both domains into certain ”higherlevel” features. The embedded ”highlevel” feature has
the direct implication of the task of interests and achieves the crosslevel information transmission
through transferring knowledge via learned representations cross domains.
Figure 4.2 shows the overall framework of CLEIT. The training of CLEIT involves five steps:
1) learning an embedding of DH from unlabeled data using standard autoencoder (AE) [111], 2) fine
tuning the pretrained embedding of DH from step 1 using a multilayer perceptron (MLP) in the
setting of multitask supervised learning, 3) and 4) learning an embedding of DL from unlabeled
data using AE along with the embedding regularization between DL samples and corresponding DH
samples in the form of an MLPbased transmitter training 5) supervised learning of the final predic
tive model of DL using an architecture that appends the pretrained multitask MLP (as a warm start)
from step 2 as well as the pretrained AE encoder and the transmitter of DL from steps 3 and 4. We
(i)

N

(i)

NH

Hu
and labeled samples as X Hl = {(xHl , y(i) )}i=1l ,
denote unlabeled DH samples as X Hu = {xHu }i=1

where NH· stands for the number of samples in corresponding data sets. Furthermore, zH· is used to
symbolize the latent vectors (embeddings) learned in different phases throughout the training. Sam
ples from the DL are similarly denoted.
Highlevel domain DH encoder training and finetuning

For the pretraining of DH , we first construct an autoencoder [111] to ”warm” the encoder
with standard input reconstruction task over the unlabeled DH samples. Then, in the finetuning step,
we append a taskspecific neural network module to retune the pretrained encoder to learn high
level taskspecific representations. In our setting, we focus on predicting the drug sensitivity of a
particular sample against a list of preselected drugs, where the anticancer sensitivity of each spe
cific drug can be seen as an individual task. To acknowledge that different drugs may have different
medicinal mechanisms, we designed the predictor module as follows. We first append one shared
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layer after the pretrained encoder module and then append nonsharing additional fully connected
layers to make a complete predictor for each task (drug). In this manner, the shared layer(s) of the
predictor and the encoder module are assumed to capture the salient biological features that are gen
erally useful for drug sensitivity prediction. And, each nonshared layer will translate such features
in accords to each drug’s specific mechanism. The drug sensitivity is metricized by a continuous
valued metric (area under the doseresponse curve), making the task a regression problem. Last but
not least, we design a masked mean squared error with ranking penalty term (shown in equation
(4.1)) as our finetuning process loss function. On the one hand, this loss allows the missing values
in the multidimension label space. On the other hand, the ranking penalty term pushes the loss to
spare some focus on the correct relative ordering of a particular drug’s sensitivity against the list of
training cell line sample instead of solely approximating the actual sensitivity measurement values.

Lsi−mse (y, by) =

1
NDrug

X

1
i
{ ∗ [y − by] · Ih
yk ̸=N A
k
j

2

2

1
i )2 }
− α · ∗ 2 ([y − by] · Ih
yk ̸=N A
(k )
j

(4.1)

where α is the corresponding weighting item for the ranking penalty term in equation (4.1) and

NDrug is the number of drugs in consideration. y ∈ Rk with potential missing values is the ground
truth drug sensitivity scores between a drug and k total samples (or the number of samples within
a batch), correspondingly, and by ∈ Rk is the predicted drug sensitivity scores. I[yk

j ̸=N A

]

is a binary

indicator vector of length k , that stands for the presence/absence of groundtruth score for this drug
against all the labeled samples and k ∗ accordingly is the total number of samples with groundtruth
sensitivity score for this drug.
Moreover, in the finetuning phase, we started with updating only appended predictor module
and then employed gradual unfreezing and layerwise decayed learning rates to update the encoder.
After the training of DH , the encoder is frozen to generate ”groundtruth” latent representation of

DH , while the appended predictor module can be preserved to serve as initialization checkpoint for
predictor module in DL to facilitate the corresponding training process.
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Lowlevel domain DL encoder and transmitter training

The pretraining procedure of DL is mostly the same as the one used for the encoder pre
training of DH . However, different from DH , where the encoder training in DH is an intermediate
step to improve the generalizability by leveraging more available unlabeled data. The pretraining
process of DL in CLEIT is also responsible for incorporating knowledge from DL to enhance the
quality of encoder representation learning.
As shown in Figure 4.2, for the encoder pretraining of DL we also use an autoencoder recon
struction task with unlabeled data. The key innovation lies in the information transmitter module
between the hidden representations of two domains. As introduced earlier, we considered the latent
representation generated by DH encoder as the ”groundtruth” representation to which DL encoder
aims to approximate. We utilize the additional transmitter module to explicitly bridge the asymmet
rical encoding process between DH and DL . Specifically, the transmitter is responsible for minimiz
ing the discrepancy between the hidden representations of two domains. Such minimization task is
formulated as a crosslevel information transmission loss (Lclr ) between representations of the same
sample from different domains. Lclr is used as additional regularization to guide the training of en
coder of DL . We then train the encoder in a multitask setting, where the training loss is defined as
a weighted combination of AE loss (LAE ) and crosslevel information regularization loss (Lclr ) as
shown below,

Lcleit = λLclr (zL , zH ) + (1 − λ)LAE (xLu , xd
Lu , zLu )

(4.2)

where λ is a userspecified hyperparameter to balance the loss terms. When λ = 0, the training does
not use any information transmitted across domains. F stands for additional transmitter module. zLu
captures the domain specific information with the autoencoder affiliated reconstruction task, while
the transmitted representation zL = F (zLu ), transformed directly from zLu , is to mimic the ”ground
truth” embedding from DH , which will be further utilized to perform downstream tasks. In the ab
sence of transmitter, zLu will be further burdened with groundtruth emebdding matching, which may
cause challenges in the actual training process. In this work, a two layer fully connected MLP is used
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as the transmitter.
We used contrastive loss in the transmitter to measure the difference between embeddings. The
contrastive loss is adopted from the selfsupervised learning framework SimCLR [112]. We consider
the embeddings of the same sample in different domains as the positive pairs, and the contrastive loss
is defined as,
(i)

(i)

(i)

Lctr (zH , zL ) = −log

(i)

exp(sim(zH , zL ))
Π

(4.3)

where

Π=
+

N
X
k=1
N
X

(i)

(k)

(i)

(k)

I[k̸=i] exp(sim(zH , zL ))
I[k̸=i] exp(sim(zL , zH ))

(4.4)

k=1

and

(i) T (k)

(i) (k)
sim(zH , zL )

=

zH zL
(i)

zH

(4.5)

(k)

zL

I[k̸=i] is the binary indicator vector of condition (k ̸= i) and the crosslevel information regulariza
tion loss is computed as the average contrastive loss between all positive pairs within one batch.
After incorporating the crosslevel information regularization loss into the encoder pre
training, we can leverage all the samples that have features in both domains regardless of the label’s
(i)

(i)

availability. We denote samples used in the pretraining phase of DL as {(xL , xH )}N
i=1 , N is the
total number of samples that have features in both domains. In the supervised finetuning phase of

DL , the inherited predictor modules from the training of DH are appended after DL encoder and
transmitter to accelerate the initial training on these modules. Like DH encoder finetuning, we also
employed similar gradual unfreezing, as well as the layerwise decayed learning rate, in the training
of encoder and transmitter modules. A detailed DL training procedure can be found in (Procedure
1).
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Procedure 1 DL training procedure
(i)

(i)

(i)

NL

(i)
l
Input: {(xL , xH )}N
i=1 , {(xLl , y )}i=1

Require: nu , number of pretraining epochs

nf , number of epochs to keep encoder frozen
nuf , number of epochs to unfreeze one more layer
α, initial learning rate in finetuning
δ , learning rate decay coefficient;
θ, all trainable parameters, begin with only predictor modules
1: for epoch = 1 to nu do
2:

Update DL autoencoder and transmitter with Lcleit

3: end for
4: for epoch = 1 to nf do
5:

Update θ with Lsi−mse

6: end for
7: epoch = 0
8: repeat
9:

if epoch %nuf == 0 then

10:

Expand θ with highest frozen layer of encoding module (pretrained encoder + transmitter)

11:

α=α∗δ

12:

end if

13:

Update θ with Lsi−mse

14: until Stop Condition

In practice, the stopping condition to terminate the finetuning of DL , can be in the form of
either prespecified maximum number of epochs or early stopping with a validation dataset.
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Experiments
Experiment Setup
Datasets

We evaluate the performance of CLEIT on a realworld problem: predicting anticancer drug
sensitivity given the mutation profile of cell lines. The mutation profile (oncology panel) has been
implemented in the clinic but has weaker discriminative power for drug sensitivity prediction than
the gene expression profile that is not a clinical standard yet. We collected and integrated data from
several diverse resources: cancer cell line data from CCLE [113], pancancer data from Xena [114],
drug sensitivity data from GDSC [93], and genegene interactions from STRING [115]. CCLE in
cludes 1305 and 1697 cancer cell line samples with the gene expression profile and the somatic mu
tation profile, respectively. The pancancer data sets include 9808 and 9093 tumor samples with
the gene expression profile and the somatic mutation profile, respectively. Specifically, we only
keep the mutation profiles of samples with matched gene expression profiles in our unlabeled mu
tation data set. All gene expression data are metricized by the standard transcripts per million base
for each gene, with additional log transformation. For the somatic mutation data, we kept only non
silent genes then propagated the mutated genes in each sample on a STRING genegene interaction
network using pyNBS [116]. We selected the top 1000 varied genes measured by the percentage of
unique values in gene expression samples for cancer cell lines and tumor tissue samples separately.
Then we combined the two sets of top 1000 varied genes as the input features. The union has 1424
unique genes in total. Additionally, we only kept the genes present in the mutation profiles as our
final raw feature sets, although CLEIT does not require it. We did so for a fair comparison to other
domain adaptation methods since all other methods in comparison consist of a shared encoder com
ponent that requires the same number of input features across domains. The final feature set consists
of 1407 genes. Furthermore, we matched the omics data of CCLE cell lines against the GDSC drug
sensitivity score measured by the Area Under Drug Response Curve (AUC), which is presented as
the fraction of the total area under the drug response curve between the highest and lowest screen
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ing concentration in GDSC [93]. In total, we assembled 680 CCLE cell lines with both mutation and
gene expression, which are associated with 93 anticancer drugs after removing drugs that have more
than 10% missing drug sensitivity measurements within these cell line samples. These 680 cell lines
and 59,203 drug sensitivity data were used as training data in the finetuning stage. 278 cell lines
have only mutation information. These data were used as holdout testing data in our study. Addi
tionally, 11,113 and 9,743 samples do not have measured drug sensitivities. These unlabeled data
were used in the pretraining stage. The gene expression profile is considered as DH , while the muta
tion is DL . A summary of the preprocessed data are shown in Table 4.1.

Table 4.1: Summary of preprocessed data for training and testing in CLEIT

Category
Gene Expression
(#cell lines)
Somatic Mutation
(#cell lines)
Drug Sensitivity
(#cell linedrug pairs)

Unlabeled
(pretraining)

Labeled
(finetuning)

Labeled
(test)

11113

680

NA

9743

680

278

NA

59203

23475

Training and testing procedure

To demonstrate CLEIT’s stable performance in the given anticancer drug sensitivity predic
tion task, we repeated the model training five times. First, we split the labeled finetuning dataset
that has both gene expression and mutation profile into 5 folds. Then, in each repetition, we used
four out of five folds as the labeled training set, the remaining one fold left as the validation set.
Moreover, the detailed training procedure of CLEIT is listed as follows. In the DH pretraining, we
trained CLEIT for N epochs. With parameter grid search, N is selected based on the target task per
formance. While for the finetuning of DH , we employed early stopping with validation labeled fold
(only gene expression) as mentioned earlier in this section. For the pretraining of DL , similar to pre
training of DH , we specified the number of epochs based on the taskspecific performance. In the
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finetuning of DL , we employed early stopping with the same validation fold (only mutation) in the
finetuning of DH . The final trained model is used to make predictions on a labeled mutationonly
test set. All other baseline models followed the same training and testing procedure.
Performance Evaluation

We evaluated CLEIT’s performance by predicting drug sensitivity on a holdout labeled
mutationonly test data. We measured the regression performance using Pearson correlation,
Spearman correlation, RMSE (root mean squared error). Note that there is a maximum of 93 drug
sensitivity scores associated with each cell line sample. The results are shown with the average
performance per cell line sample (samplewise) and per drug (drugwise). Besides, because of the
incompleteness of the ground truth matrix, the prediction entries without a ground truth sensitivity
score are filtered out in the calculation of each evaluation metric.

Baseline models

We compared CLEIT with the following baseline models: MLP without and with the AE
pretraining for DL as well as several of the most popular domain adaptation algorithms that are
used to transfer the knowledge learned from DH to DL . They include Deep Domain Confusion
(DDC) network [76], Correlation Alignment (CORAL) [79], Domain Adversarial Neural Network
(DANN)[83], Adversarial Domain Adaptation Network (ADDA) [84] and Domain Separation Net
work (DSN) [89]. Specifically, DDC, CORAL, DANN, and ADDA only made use of the labeled
data (same dataset and procedures adopted in the finetuning phases of CLEIT), while DSN utilized
both the unlabeled and labeled data (same dataset and procedures adopted in the pretraining and
finetuning phases of CLEIT). For domain adversarial loss in DSN, we employed the MMD variant
for the stability of training.
To evaluate the contribution of different components in CLEIT, we performed ablation studies
by 1) removing the transmitter, 2) change the crosslevel transmission loss function to Maximum
Mean Discrepancy (MMD) loss [74] and Earth Mover distance approximated using Wasserstein
GAN (WGAN) [117]. The latent dimension for hidden representation for all models is specified as
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128, and all autoencoder frameworks share the same [512, 256, 128, 256, 512] architecture. Besides,
all pretrained encoders will be appended with a predictor module of the same architecture ([128]
shared layer + [64,32] individual drug MLP) for the finetuning process.

Results and Discussion
Gene expression feature has stronger predictive power than somatic mutationbased feature

Figure 4.3 shows that the performance comparison between the regression models trained us
ing only gene expression features and those trained by only somatic mutation features to predict anti
cancer drug sensitivity. Two neural network models were compared. One was to use an unlabeled
pretrained encoder (denoted as MLP+AE), and the other was to use a randomly initialized encoder
(denoted as MLP). All models compared here were trained and tested using the labeled finetuning
dataset listed in Table 4.1 based on the fivefold crossvalidation because we need the exact same
testing cases with both gene expression and somatic mutation data. Consistent with extensive per
formance evaluations from blind tests in a DREAM challenge [97], and other studies [100], the gene
expression feature has more substantial predictive power than the mutationbased feature. As shown
in Figure 4.3 (a), the model trained with only labeled gene expression data has a 6.45% performance
gain over the model trained with corresponding labeled somatic mutation data when evaluated us
ing a samplewise average. With the additional utilization of unlabeled pretraining, models trained
with only gene expression data and only the mutation data both showed slightly better performance,
while their performance gap is around 6.8%. In terms of drugwise average, as shown in Figure 4.3
(b), the performance gap between models built on mutationonly and expression only data is even
more apparent. These results confirmed that the gene expression is more predictive than the somatic
mutation for predicting the anticancer drug sensitivity.
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(a) SampleWise Average

(b) DrugWise Average

Figure 4.3: Performance comparison of the model trained using only gene expression features with that using
only somatic mutation features, and tested with the same data set.

CLEIT can transfer the knowledge learned from gene expression features to the model with
mutation features

To demonstrate that CLEIT can transfer the knowledge learned from the gene expression fea
ture to the model that uses the mutationonly data, we compared the drugwise Pearson correlation
distribution of CLEIT with those of the MLP+AE models trained with only gene expression or mu
tation data. Figure 4.4 shows the histogram of Pearson correlations of 93 drugs for three models.
CLEIT with the mutation data shifts the performance distribution close to the model trained using
the gene expression data, which has significantly better performance than the MLP+AE model with
the mutation data. It is aligned with our primary goal in this work. Note that the histograms in Fig
ure 4.4 were from the validation data. Next, we evaluate the performance of CLEIT in a holdout
mutationonly test data.

CLEIT significantly outperforms stateoftheart models to predict anticancer drug sensitivity
using mutationonly data

Given that gene expression data have stronger predictive power than somatic mutation data, we
evaluate if CLEIT can use the gene expression to boost the performance for predicting anticancer
drug sensitivity when only the somatic mutation data are available as the input. The results for both
drugwise and samplewise evaluation are shown in Table 4.2 and Table 4.3. As seen in those tables,
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Figure 4.4: Drugwise pearson correlation on validation dataset.

Table 4.2: Evaluation Results on Test Data (Drugwise).

Method
MLP (mutationonly)
MLP+AE (mutationonly)
DDC[76]
CORAL[79]
DANN[83]
ADDA[84]
DSN[89]
CLEIT (w/o transmitter)
CLEIT (MMD)
CLEIT (ADV)
CLEIT

Pearson
0.0591±0.0069
0.0681±0.0085
0.0633±0.0087
0.0580±0.0105
0.0571±0.0061
0.0681±0.0111
0.1003±0.0186
0.2587±0.0126
0.1758±0.0086
0.0795±0.0083
0.2770±0.0086

Spearman
0.0532±0.0066
0.0629±0.0108
0.0621±0.0087
0.0542±0.0080
0.0516±0.0038
0.0685±0.0142
0.0915±0.0252
0.2254±0.0348
0.1421±0.0200
0.0821±0.0106
0.2482±0.0243

RMSE
0.0233±0.0018
0.0151±0.0001
0.0150±0.0006
0.0164±0.0005
0.0173±0.0010
0.0197±0.0010
0.0147±0.0007
0.0124±0.0006
0.0148±0.0009
0.0150±0.0009
0.0121±0.0006

models that consist of unlabeled pretraining processes generally outperform the models trained with
only labeled data, indicating the importance of leveraging unlabeled data. The models trained with
domain adaptation methods with unlabeled pretraining (DSN or CLEITs) or only labeled training
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Table 4.3: Evaluation Results on Test Data (Samplewise).

Method
MLP (mutationonly)
MLP+AE (mutationonly)
DDC[76]
CORAL[79]
DANN[83]
ADDA[84]
DSN[89]
CLEIT (w/o transmitter)
CLEIT (MMD)
CLEIT (ADV)
CLEIT

Pearson
0.7390±0.0017
0.7450±0.0003
0.7449±0.0017
0.7439±0.0013
0.7428±0.0017
0.7315±0.0053
0.7470±0.0002
0.7569±0.0081
0.7443±0.0018
0.7465±0.0005
0.7640±0.0094

Spearman
0.6957±0.0022
0.6984±0.0004
0.7010±0.0010
0.7002±0.0010
0.6995±0.0019
0.6891±0.0010
0.7024±0.0004
0.7172±0.0070
0.7003±0.0009
0.7022±0.0008
0.7233±0.0063

RMSE
0.0235±0.0017
0.0150±0.0001
0.0151±0.0004
0.0165±0.0004
0.0174±0.0008
0.0199±0.0008
0.0148±0.0004
0.0125±0.0005
0.0147±0.0009
0.0152±0.0009
0.0122±0.0005

outperform their nonadaptation counterparts. It implies that DL will benefit from the knowledge
transfer from DH . Furthermore, CLEIT models significantly outperform all other models in consid
eration (ttest pvalue < 0.05). The bestperformed model is the CLEIT that uses contrastive loss.
Compared with the best performed stateoftheart model (DSN), the accuracy of CLEIT, when mea
sured by Pearson correlation, improves 277% and 2.2% for the drugwise and the samplewise test,
respectively. Similar results can be seen in terms of Spearman correlation and RMSE. The perfor
mance gain of CLEIT over MLP and MLP+AE is 3.4% and 2.5%, respectively, in the samplewise
setting, yet in the drugwise setting, the improved gap is enlarged to 469% and 407%. The much im
proved drugwise performance achieved by CLEIT indicated a much higher quality drugsensitivity
prediction with the mutationonly data.
CLEIT models that incorporate MLPtransmission function show significantly better perfor
mance than those without, suggesting that the transmission function plays a role in CLEIT. Choice of
the loss function in the information transmission is also important. It is clear that contrastive loss per
forms better than MMD and WGAN. It is noted that MMD is used in DSN. When CLEIT uses MMD
as the loss function to measure the domain discrepancy, the major difference between CLEIT and
MMD is that CLEIT treats the information transmission between two domains asymmetrical, while
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DSN considers domain adaptation symmetrical. The results in Table 4.2 and Table 4.3 show that
CLEITMMD outperforms DSN in drugwise setting and perform similarly in samplewise settings.
It indicates that the explicit modeling of the hierarchical organization of DL and DH is important.

CLEIT outperforms stateofthearts for predicting topranked cellline specific anticancer
therapies

Furthermore, CLEIT can predict the best therapy for a new patient using only mutation data
for personalized medicine. We compared the performance of different methods with the precision of
topk (k = 1, 3, 5, 10) predictions ranked by the AUC scores, which is defined as the ratio of drugs
with topk smallest predicted scores per cell line among the drugs with topk groundtruth scores.
Mutationonly test results can be found in Figure 4.5. Clearly, the CLEIT model also outperforms
other models in this scenario. Compared with the secondbest performed model DSN, CLEIT im
proves the performance by approximately 11% when k = 3.

Conclusion

This paper proposed a novel machine learning framework CLEIT for the predictive modeling
of genotypephenotype associations by explicitly modeling the asymmetric crosslevel information
transmission in the biological system. Using the anticancer drug sensitivity prediction with only
mutation data as a benchmark, CLEIT clearly outperforms existing methods and demonstrates its po
tential in personalized medicine. Although we only study the knowledge transfer between DNA level
and RNA level in this paper, the same strategy can be applied to other levels in the biological system,
for example, imputing proteomics data using transcriptomics data. Nevertheless, the performance of
CLEIT could be further improved by incorporating domain knowledge. For example, an autoencoder
module that can model genegene interactions and biological pathways will be greatly helpful. Under
the framework of CLEIT, it is not difficult to integrate other omics data such as epigenomics and pro
teomics. They may further improve the performance of CLEIT. Another challenge in personalized
medicine is to transfer knowledge from cell line data to patient tissue data [118]. It will be interesting
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to develop new neural network architectures in the framework of CLEIT to address this problem.
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Chapter 5
COherent Cell lineTissue DEconfounding Autoencoder (CODEAE)

Introduction

Transcriptomics is a powerful technique to characterize cellular activity under various condi
tions, allowing researchers to uncover the underlying associations among genes, biological pathways,
diseases, and environmental factors. Hence, this data source has been widely explored by studies
ranging from regulatory gene identification [11, 12] to disease biomarker discovery [13]. In partic
ular, it has been utilized to construct predictive machine learning models for drug response, such as
in [15, 16]. However, the success of such predictive models largely relies on the availability of suf
ficient amounts of data with coherent and comprehensive annotations. In clinical, we are often short
of a large number of patient samples with drug treatment and response history. For this reason, most
drug response predictive studies to date have mainly utilized transcriptomic profiles from panels of
invitro cancer cell lines as input features. Although such an approach is promising, the utility of
drug response models built with invitro data is often limited when applied to real patients due to the
genetic and environmental differences between invitro cell lines and patientderived tissue samples
and confounding factors that may mask intrinsic biological signals.
To address the above challenges, we propose a Coherent Cell lineTissue Deconfounding Au
toencoder (CODEAE) that can extract both common biological signals shared by incoherent sam
ples and private representations unique to them, transfer knowledge learned from cell line data to
tissue data, and separate confounding factors from them. CODEAE will allow us to generalize ex
isting cell line omics data for robust predictive modeling of drug response to new patients, a critical
component for patientspecific drug screening and precision medicine. Specifically, in CODEAE,
we devise a selfsupervised training scheme to construct an encoding module that can be easily tuned
to adapt to the different downstream tasks. For the selfsupervised training of encoder, we leverage
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both unlabeled cell line and tissue samples.
As a demonstration of the potential of CODEAE in precision medicine, we apply CODEAE
to predicting chemotherapy resistance for patients, which is a significant obstacle to effective can
cer therapy. Lack of effective personalized chemotherapy tailored to individual patients often leads
to unnecessary suffering and reduces the chances of patient’s overall survival. Our extensive stud
ies show that CODEAE significantly outperforms stateoftheart methods in terms of both accu
racy and robustness. Thus CODEAE provides a useful framework to take advantage of rich in vitro
omics data for developing generalized patient predictive models.

Related Works

Our goal is to learn an encoding function that maps a gene expression profile to a low
dimensional vector (embedding) dominated by intrinsic biological signals from both invitro cell
lines and invivo tissue samples. For such representation learning problems, a wellestablished tech
nique is an autoencoder (detailed in Chapter 2) and its variants, such as DAE[119] and VAE[120],
due to their low reliance on labeled data availability. In addition, CODEAE also considers this
invitro and invivo sample differences close to the classifical domain adaptation task settings, we
also explored the featurebased domain adaptation techniques detailed in Chapter 2. Moreover, a
recent publication Adversarial Deconfounding Autoencoder [121], which incorporates autoencoder
and alternative adversarial training for similar goal as CODEAE is also included in our benchmark
experiments.

Methods
Our Approach: COherent DEconfounding AutoEncoder (CODEAE)

We proposed the CODEAE to generate biologically informative gene expression embeddings
applicable to transfer between invitro and patient samples. CODEAE employed the standard auto
encoder as the backbone to leverage the unlabeled gene expression data sets. Inspired by the work on
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factorized latent space [122] and domain separation network [89], we encoded the samples (from cell
lines or tumor tissues) into two nonredundant embeddings, namely private embeddings and shared
embeddings. The first one is designed to capture the cell line or tissuespecific information. The lat
ter contains the deconfounded biological meaningful information used to transfer knowledge across
cell lines and tissues.
CODEAE Base

Figure 5.1: COherent Deconfounding AutoEncoder (CODEAE) framework. a) CODEAE Base architecture:
A layertying shared encoder Es learns to map both cell line and tissue samples to deconfounded biological
meaningful embeddings. Private encoders E·p learn to represent cell line/tissue specific information as private
embeddings. A shared decoder D reconstructs the input samples through the concatenation of private and
shared embeddings and the reconstruction quality is measured with Lrecon . The private and shared
embeddings are pushed apart through soft subspace orthogonality loss Ldif f b) Appended module of
CODEAEMMD: the concatenation of private and shared embeddings are kept similar with LM M D c)
Appended module of CODEAEADV: the concatenation of private and shared embeddings are kept similar
with Ladv , where Ladv is in the form of minmax optimization between critic network F and other
components.

As shown in Figure 5.1, the CODEAE takes expression vectors from invitro cell lines and pa
n

o
(i) Nt

tient tumor tissue samples as input. Let Xt = xt

i=1

n

and Xc = x(i)
c

oNc
i=1

represent the unlabeled
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data set of Nt patient tumor tissue samples and Nc invitro cancer cell line samples, respectively.
Each sample x will be encoded into two separate embeddings through its corresponding cell line or
tissue private encoder E·p and also the weightsharing encoder Es . The concatenation of these two
embeddings of each sample is expected to be able to reconstruct the original gene expression vector

x through a shared decoder D, and the reconstruction is done as,
M

d
(i)

x· = D(Es (x(i)
· )

E·p (x(i)
· ))

(5.1)

d
(i)

where x(i)
· represents the input gene expression profile, x· is the corresponding reconstructed input
sample through the autoencoder component.

L

stands for the vector concatenation operation. We

measure the quality of autoencoder reconstruction through the mean squared error between the origi
nal samples and the reconstruction output as below,

Lrecon =

Nc
1 X
d
(i)
x(i)
c − xc
Nc i=1

2

+
2

Nt
1 X
d
(i)
(i)
xt − xt
Nt i=1

2

(5.2)
2

In our formulation, we factorized each sample’s latent space into two different subspaces to capture
both domain specific and common information separately. To minimize the redundancy between the
factorized latent spaces, we included an additional penalty term, Ldif f in the form of orthogonality
constraint. The difference loss Ldif f , is applied to both cell line and tissue samples and encourages
the shared and private encoder to encode different aspects of the inputs. We define the loss via soft
subspace orthogonality constraint as below,

Ldif f = ZTcs Zcp

2
F

+ ZTts Ztp

2
F

(5.3)

where Z·s are the embedding matrices whose rows are the shared embedding for cell line or tissue
samples, while Z·p are the embedding matrices whose rows are the private embedding for cell line or
tissue samples. It is obvious that Ldif f tends to push the embeddings to meaningless allzerovalued
vectors. To avoid such scenario, we append an additional instance normalization layer after the out
put layer of each encoder to avoid embeddings with minimal norm. Lastly, the loss for CODEAE
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BASE is defined with the weighted combination between Lrecon and Ldif f as below,

Lcode−ae−base = Lrecon + αLdif f

(5.4)

where α is the embedding difference loss coefficient.
CODEAE Variants

With CODEAEBASE, we could split cell line or tissue sample’s inherent information into
the private and shared streams. However, in our baseline experiments, we often found that it was
suboptimal or demonstrated varied performance. Thus, in this section, we proposed two variants
that showed better and generally more stable performance. Under the CODEAE framework, for
each input sample, CODEAE factorized it into two embeddings. The concatenation of these two em
beddings is considered as the new representation of the original input. Given that all samples in our
consideration are gene expression profiles regardless of cell line or patient, we assumed that the new
representation of original input in the factorized latent space close to each in terms of distributional
differences.
CODEAEMMD. The first variant, named CODEAEMMD, utilized the well known max

imum mean discrepancy [74] as the distance measurement between the latent representation of cell
line and tissue samples. Maximum Mean Discrepancy (MMD) loss [74] is a kernelbased distance
function between samples from two distributions. In particular, we used an approximate version of
exact MMD loss in CODEAEMMD as below,

LM M D (Zc , Zt ) =
−

N
N
1 X
1 X
(i) (j)
(j)
κ(z(i)
,
z
)
+
κ(zt , zt )
c
c
N2 i,j=0
N2 i,j=0
N
2 X
(j)
κ(z(i)
c , zt )
2
N i,j=0

(5.5)

where Zc , Zt are embedding matrices for cell line and tissue samples respectively, whose rows are
the concatenations of each sample’s private and shared embedding. z·(i) , z(j)
· are the ith or j th sam
ples’ corresponding embedding vectors. In practice, N will be the batch size. Accordingly, the loss
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of CODEAEMMD is given as below,

Lcode−ae−mmd = Lcode−ae−base + βLM M D

(5.6)

where β is the MMD loss coefficient.
CODEAEADV The second variant, CODEAEADV, employed adversarial training to push

the representations of cell line and tissue samples to be similar to each other. Specifically, we ap
pended a critic network F that scores representations with the objective that consistently gives higher
scores for representations of cancer cell line samples. The encoders for tissue samples are given an
additional objective to generate the embedding that could fool the critic network to produce high
scores. In this manner, critic network and tissue sample encoders will play a minmax game in the
form of an alternative training schedule, which is adopted by Wasserstein generative adversarial net
works [87]. To avoid unstable training commonly existing in alternative training schedules, instead
of standard WGAN [87] we used the WGAN with gradient penalty [117]. Its affiliated loss terms are
defined as below,




Lcritic









Ladv : 











where z· = z·s

L

=

1
Nt

PNt
i=1

(i)

F (zt ) −

1
Nc

PNc
i=1

F (z(i)
c )

+λ(∥▽ez F (ez)∥2 − 1)2

Lgen = − N1t

PNt
i=1

(5.7)

(i)

F (zt )

z·p stands for new representation of input and ez = ϵzc + (1 − ϵ)zt and ϵ ∼ U(0, 1).

A detailed CODEAEADV learning procedure can be found in (Procedure 2).
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Procedure 2 CODEAEADV training
(i)

(i)

Nt
c
Input: {xc }N
i=1 , {xt }i=1

Require: N , the batch size
λ, generator loss coefficient
nw , number of warmup epochs
nt , number of training epochs
ncritic , number of steps per encoders update
1: for epoch = 1 to nw do
min(Nc ,Nt )
2:
for t = 1 to
do
N
3:

(i)

c
sample {xc } of size N from {xc }N
i=1 (w/o. rep)

(i)

t
4:
sample {xt } of size N from {xt }N
i=1 (w/o. rep)
5:
Update Etp , Ecp , Es , D with Lcode−ae−base
6:
end for
7: end for
8: for epoch = 1 to nt do
min(Nc ,Nt )
9:
for t = 1 to
do
N

10:

(i)

c
sample {xc } of size N from {xc }N
i=1 (w/o. rep)

(i)

t
11:
sample {xt } of size N from {xt }N
i=1 (w/o. rep)
12:
Update F with Lcritic
13:
if t %ncritic == 0 then
14:
Update Etp , Ecp , Es , D with Lcode−ae−base + λLgen
15:
end if
16:
end for
17: end for

After the encoder training with unlabeled data as mentioned above, the shared encoder Es
could be used to directly generate the deconfounded biological meaningful embedding vectors or
append a neural network module for specific downstream tasks. In the latter case, strategies such
as gradual unfreezing and decayed learning rate schedule could be adopted to improve taskspecific
performance further, as shown in our following experiments.
Experiments Setup
Baseline models

We compared CODEAE with the following baseline models: standard autoencoder (AE)
[111], denoising autoencoder (DAE) [119], and variational autoencoder (VAE) [120] as well as rep
resentative domain adaptation methods including deep coral (CORAL) [80] and domain separation
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network (DSN) [89] of both MMD (DSNMMD) and adversarial (DSNADV) training variants. Fur
thermore, we included a more recent adversarial deconfounding autoencoder (ADAE) [121] given its
similar formation as DANN [83] and stateoftheart performance in transcriptomics data sets. For
fair comparisons, all the encoder and decoder trained in the experiments share the same architecture.
Specifically, the hidden representation is of dimension 128. The encoders and decoder are 2layer
neural network modules of dimension (512, 256) and (256, 512), respectively, with the rectified lin
ear activation function. Appended modules such as critic network in CODEAEADV, and classifier
network used for finetuning are 2layer neural networks of dimension (64, 32) with rectified linear
activation, have one output node with linear activation in critic network and sigmoid activation in
classifier networks. Further, the loss weight terms in CODEAEMMD and CODEAEADV are all
simply specified as 1.0.
For reference, we also included the classification performances of similarly finetuned ran
domized initialized encoder (labeled as MLP). In addition, the elastic net classifier (labeled as EN)
trained on original cell line gene expression profiles also included in the comparison.
Data sets

We evaluated the performance of CODEAE with a practical problem: predict chemotherapy
resistance given gene expression profiles of patients while training the predictive model only using
the gene expression of cancer cell lines. We collected the cancer cell line gene expression profiles
from the DepMap portal [113] and corresponding drug sensitivity data from GDSC [93, 94]. Addi
tionally, we collected patients’ tumor tissue gene expression profiles from the Xena portal [114]. In
total, we gathered 1305 cancer cell lines and 9808 patient tumor tissue samples with corresponding
gene expression profiles, respectively. All gene expression data are metricized by the standard tran
scripts per million base for each gene, with additional log transformation.
Clinical chemotherapy resistance can be defined as either a lack of reduction in the size of tu
mor following chemotherapy or the occurrence of clinical relapse after an initial “positive response
to treatment” [105]. Hence, we extracted data sets to assess these two aspects. The patient clinical
drug response was acquired from a recent work [123], where patients’ clinical response records of
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two chemotherapy agents Gemcitabine and Fluorouracil from The Cancer Genome Atlas (TCGA)
[95] were extracted. The patients were split into two groups: responders who had a partial or com
plete response and nonresponders who had a progressive clinical disease or stable disease diagnosis.
Only patients on singledrug therapy through the entire duration of treatment were retained in the
study.
In addition to using clinical diagnosis to indicate patients’ drug responses towards a particular
drug, we extracted patients ”new tumor events days after treatment” from TCGA [95] as the stan
dard to divide patient into responders and nonresponders. The median number of days of new tumor
events was used as the threshold. Similar to the above data set from [123], we only included patients
on singledrug therapy through the entire treatment duration in this test data set. Due to the limited
size of patients’ samples, we only included patients who received Cisplatin and Temozolomide in
this test data set.
Training procedure

We selected the top 1000 varied genes measured by the percentage of unique values for cancer
cell lines and tumor tissue samples separately. Then we combined the two sets of top 1000 varied
genes as the input features. The union has 1424 unique genes in total. We first pretrain different
variants of the autoencoders as mentioned above using the same unlabeled samples from both cancer
cell lines and tumor tissues. Then we finetune the pretrained encoders with appended classification
module over labeled cancer cell line samples and corresponding drug sensitivity data. Specifically,
we first selected all cell lines with corresponding drug sensitivity measured in the area under the drug
response curve (AUC). We further categorized these cancer cell lines’ sensitivity against this drug
into binary labels, namely resistant or responsive. In particular, for the drug sensitivity measured in
AUC, it was presented as the fraction of the total area under drug response curve between the highest
and lowest screening concentration in GDSC [93, 94]. We set the AUC threshold as the value that
produced the best classification performance of an elastic net classifier given different drugs. The
number of training cell line samples (responsive/resistant) and test tumor tissue samples for differ
ent drugs sensitivity prediction tasks are summarized in Table 1. During the finetuning stage, the
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Table 5.1: Training/Test samples class distribution in CODEAE

Gemcitabine
Fluorouracil
Cisplatin
Temozolomide

Training (cancer cell lines)
responsive
resistant
301
376
23
644
291
377
19
660

Test (patient tumor tissues)
responsive
resistant
37
55
34
24
20
20
25
24

cell line samples were split into ten stratified folds (according to cancer types). In one evaluation it
eration, nine out of ten folds of the samples were used as the training set. The remaining one fold of
samples was used as the validation data set for early stopping of finetuning process.
Performance evaluation

We choose the area under the receiver operating curve (AUROC) as the measurement metric
due to their insensitivity to changes in the test data set’s class distribution [124]. The model perfor
mance was measured in AUROC over the patient tissue expression data and corresponding drug re
sponse records. The performance of different methods was compared by the average of AUROCs of
ten iterations. It is noted that only cell line data were used for the model training and hyperparameter
selections, and all patient data were purely used for the testing.
Results and Discussion
Chemotherapy resistance prediction

We evaluated clinical chemotherapy resistance in two aspects: either a lack of reduction in the
size of tumor following chemotherapy or the occurrence of clinical relapse after an initial “positive
response to treatment” [105] as described in Section 4.2. The results are shown in Figure 5.2 and
Figure 5.3, respectively. Based on these results, we have the following observations.
Observation 1. CODEAEADV significantly outperforms the stateoftheart methods.

On average, CODEAEADV shows the highest value of AUROC for all four drugs tested. We
performed a twosample ttest on the AUROC performance between CODEAEADV and the best
nonCODEAE method for each drug, as shown in Table 5.2. Among three of four drugs (Gemc
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Figure 5.2: The left and right figures show the performance of different methods trained with the drug
sensitivity of cancer cell lines for predicting patients’ response to chemotherapy agents Gemcitabine and
Fluorouracil, respectively. Patients’ drug responses are measured with clinical diagnosis.

itabine, Cisplatin, and Temozolomide), CODEAEADV significantly outperforms other methods.
For the drug Fluorouracil, the performance CODEAEADV does not significantly improve the
secondbest performer VAE, but is significantly better than other stateoftheart methods CORAL
and ADAE. Moreover, CODEAEADV is more robust than other methods, as demonstrated by rela
tively smaller variants of the performance.
Observation 2. Private and shared embeddings of cell line and patient data contribute to
improving the performance of transfer learning. The major difference between CODEAEADV

and ADAE is to disentangle shared and private embeddings between cell lines and patient tissues. It
is also true for the difference between DSNADV and ADAE. For all four drugs, CODEAEADV
significantly outperforms ADAE. Among three of four drugs (Fluorouracil, Gemcitabine, and Cis
platin), DSNADV also performs significantly better than ADAE. For the drug Temozolomide, the
performance difference between DSNADV and ADAE is not statistically significant (pvalue =
0.194747).
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Figure 5.3: The left and right figures show the performance of different methods trained with the drug
sensitivity of cancer cell lines for for predicting patients’ response to chemotherapy agent Cisplatin and
Temozolomide, respectively. Patients’ drug responses are categorized based on number of days of new tumor
events after treatment.

Observation 3. Adversarial loss outperforms MMD loss. For all four drugs, CODEAE

ADV and DSNADV significantly outperform their variants CODEAEMMD and DSNMMD,
respectively. The only difference between them is the loss function, adversarial loss or MMD loss.
Clearly, transfer learning between cell lines and patients may benefit from the adversarial training
that provides an effective way to sample the learning space.

Table 5.2: Average AUROC performance ttests pvalues

Drug
Gemcitabine
Fluorouracil
Cisplatin
Temozolomide

Best Non CODEAE method
DSNADV
VAE
DSNADV
CORAL

Pvalue
0.010894
0.205175
0.033298
0.000557
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Transferability of deconfounded representation of CODEAE

To show that CODEAE can generate transferable embedding through deconfounding uninter
esting confounders while preserving true biological signals present in expression data even outside
the invivo and invitro setting. We selected the gene expression data sets used in ADAE [121] to
perform a similar evaluation process. Specifically, we chose the brain cancer expression data set
with gender information as confounding factors and brain cancer subtype classification as target
downstream tasks. We first performed encoder training with all unlabeled gene expression profiles
regardless of gender. For ADAE [121] and CODEAE, we selected the binary gender variable as
the deconfounding target. After encoder training, we generated the latent embedding for all original
gene expression profiles using different encoders. Then, we built elastic net classifiers for cancer
subtype prediction using the latent embedding of samples of one gender to predict the other gender
samples. Following the evaluation procedure described in [121], the classification performance mea
sured in the area under the precisionrecall curve (AUPRC) as well as area under the receiver oper
ating curve (AUROC) of tenfold crossvalidation was reported in Table 5.3. Besides, we performed
a twosample ttest on the average performance between CODEAE and the best nonCODEAE
method in each setting, and its results are shown on the last row of Table 5.3. We observed the same
trends as those in the drug resistance prediction. Using the model built from female data to predict
male data, CODEAEADV significantly outperforms ADAE, the secondbest performer measured
by both AUROC and AUPRC. When applying the model trained from male data to predict female
data, the performance of CODEAEADV is slightly worse than CORAL, but the difference is not
statistically significant. Both CODEAEADV and CORAL significantly outperform the stateofthe
art deconfounding method ADAE (pvalue ≤ 0.05). Additionally, two other observations from the
chemotherapy resistance experiments hold. Disentangling common and private features of different
data modalities is essential for cell line to tissue transfer learning, and adversarial loss is more effec
tive than MMD loss.
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Table 5.3: The best and the second best performances are highlighted and underlined, respectively

ADAE
CORAL
DSNMMD
DSNADV
CODEAEBASE
CODEAEMMD
CODEAEADV
P value of ttest

Female>Male
AUROC
AUPRC
0.9038±0.0081 0.9621±0.008
0.8793±0.0208 0.9432±0.0042
0.6772±0.0187 0.8715±0.026
0.7513±0.0341 0.9016±0.0086
0.603±0.0437 0.8613±0.0001
0.9221±0.0186 0.9683±0.0056
0.9319±0.0018 0.9730±0.0007
9.609e07
0.0018956

Male>Female
AUROC
AUPRC
0.9264±0.0043 0.9755±0.0018
0.9444±0.0057 0.9862±0.002
0.6693±0.0584 0.9145±0.0189
0.8518±0.035 0.9608±0.0098
0.6276±0.0687 0.9112±0.0079
0.939±0.0039 0.9826±0.0021
0.9400±0.0074 0.9840±0.0033
0.157513
0.08213

Conclusion

In this paper, we introduce a new transfer learning framework CODEAE to predict patient
drug response from a supervised neural network model trained from cell line data. Extensive bench
mark studies demonstrate the advantage of CODEAE over the stateoftheart in terms of both accu
racy and robustness. The performance gain of CODEAE mainly comes from (1) the unsupervised
learning that combines unlabeled data from both cell lines and patient samples, (2) separation of
shared common features cross cell lines and patient samples with unique embedding for cell lines
or patients, and (3) adversarial training to optimize the similarity and difference between incoherent
data sets. CODEAE could be further improved in several directions. In contrast with cell line data
from a pure population of cells, patient tissue data are mixtures of normal, abnormal, and infiltrated
immune cells. We can further improve the CODEAE by the deconvolution of patient gene expres
sion data. We only use transcriptomics profiles to build the predictive model in this study. We can in
tegrate additional omics data such as somatic mutations and copy number variants in the framework
of crosslevel information transmission [125]. Finally, we only apply CODEAE to cancers. It will
be interesting to test the performance of CODEAE in other diseases besides cancers, which even
do not have a large number of cell line data. In principle, CODEAE can be applied to other transfer
learning tasks with two data modalities with shared and unique features.
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Chapter 6
Summary & Prospects

How to better leverage unlabeled data is critical to robustly apply machine learning methods
to biomedical studies. In my dissertation, I focused on developing novel unsupervised representa
tion learning algorithms to improve the predictive modeling performance using noisy, incoherent,
and sparse omics data. The fundamental assumption of the usefulness of unsupervised representa
tion learning lies on the assumption that the factors (representation) that are helpful for the unsu
pervised tasks can also be useful for related supervised tasks. And it can be achieved through a di
rect mapping from lowlevel sensory data first, or via a pretraining procedure in the context of the
deep supervised network. Apparently, with the rapid advancement of deep learning in recent decade,
deep learningbased representation learning approaches attracted most of the attentions, compared
with conventional shallow modelbased approaches, where only a “single layer”transformation is
learned based on certain assumption over the new representation. Specifically, deep learningbased
approaches learn distributed representations, which encourages the reuse of features to represent
the concepts. Moreover, the deep neural networks have multiple hidden layers, where each layer
performs feature construction from the layers before it and the training process used allows layers
deeper in the network to contribute to the refinement of earlier layers. Therefore, essentially, a deep
architecture can be considered as formed by a hierarchical composition of multiple levels of repre
sentations, which naturally leads to more progressively abstract features at higher layers of the archi
tecture. This fact highlights the theoretical advantages of deep learning, i.e., learning a hierarchy of
features.
Moreover, a deep model is seen as a universal function approximator due to the exponential
representation power brought by the depth of the network as well as embedded nonlinear activation
in hidden layers. Such flexibility leads to multiple stateofart models in a diverse array of tasks.
However, to properly fit the hidden layers requires a large set of training data to avoid overfitting,
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which impedes the adoptions of deep learning approaches in biomedical studies. One typical solu
tion to overfitting, just like any other machine learning approaches, is to incorporate some external
information in the model to constrain its flexibility in the form of regularization techniques such as
the ones used in the variants of basic autoencoders. Besides, deep learning models are notoriously
difficult to train. On the one hand, it usually requires a very long computation time as well as pow
erful hardware. On the other hand, there are often multiple hyperparameters used in one deep model,
such as number of layers, number of nodes each layer, activation functions and so on, to make the
optimum choice of hyperparameters is often thought as impossible, and most of the time it relies on
the instincts from researchers’ previous experience instead of theoretical support.
The lack of a common objective in representation learning makes it very difficult to measure
the “goodness” of the representation. Usually, we refer to the “usefulness” of representations in re
lated supervised tasks as an indirect measurement. Another thing needs to be pointed out is that since
the unsupervised models are not directly trained with the supervised objective, the downstream su
pervised tasks’ performance is not theoretically guaranteed to be improved, although such regime
empirically shows boosted performance in related supervised tasks.
The interpretability of the learned representation is another critical aspect of applications of
representation learning over multiomics studies, since in biomedical studies, the findings are ex
pected to be used to answer fundamental biological problems or elucidate the new biological mecha
nism, and in the end ideally support or aid clinicians’ bedside decisions. Without appropriate biolog
ically meaningful interpretation, the success in machine learning tasks will not necessarily guarantee
the acceptance from domain experts such as biologists and clinicians.
Therefore, developing practical unsupervised representation learning methods targeted on
biomedical problems requires us to introduce the most salient related prior knowledge into the model
design as well as the learning process. In the works included in my thesis, by leveraging the hier
archical relationships among omics data at different levels, I proposed CrossLEvel Information
Transmission network (CLEIT). CLEIT aims at the predictive modeling of genotypephenotype as
sociations by explicitly modeling the asymmetric crosslevel information transmission in the biolog
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ical system. When applied to the task of the anticancer drug sensitivity prediction, CLEIT could
improve such task’s performance when only somatic mutation data is available.
Moreover, via explicitly deconfounding the confounding factors such as data source origins,
I proposed COherent DEconfounding Autoencoder (CODEAE). CODEAE is capable of learn
ing an encoding function that maps a gene expression profile to a lowdimensional vector (embed
ding)dominated by intrinsic biological signals from both invitro cell lines and invivo tissue samples.
It could improve patient drug response prediction from a supervised neural network model trained
from only invitro cell line data.
Despite the progress made, unsupervised representation learning’s application to multiomics
data studies is still in its early stage. Innovative ideas and designs are in desperate needs to uncover
the underlying biological knowledge of the everincreasing biomedical datasets and better understand
the complete biological system. In particular, for multiomics datasets, techniques such as attention
mechanism [126] and graph neural network [127] could be incorporated into existing frameworks,
such as CLEIT and CODEAE, such that the interactions between biological entities (i.e. genes)
could be used to improve the overall performance. Another critical direction is to devise innovative
approaches to organize the available datasets and design appropriate selfsupervised learning tasks
for the model training such that to further relieve the needs for labeled datasets.
The overall machine learning applications in biomedical studies are still far away from its own
”BERT” [8] moment. However, with the constant emergence of more effective and accurate bio
sensing techniques, we will be able to access biomedical dataset at even more granular levels, such
as the single cell sequencing [128], which will boost our chances to achive more accurate modelling
over diverse biomedical problems. Undoubtedly, the hope remains high, the mystery around human
body and biology will be solved scientifically in the future.
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